

ALL. B

Decreto Rettore Università di Roma “La Sapienza” n. 1859/2023 del 12/07/2023

## Antongiulio Faggiano Curriculum Vitae

Roma  
20/07/2023

### ai fini della pubblicazione

#### Part I – Education

Type	Year	Institution	Notes (Degree, Experience,...)
University graduation	1997	Federico II University of Naples	Degree in Medicine 110/110 cum laude - Prof. Lombardi and Prof. Colao
Post-graduate studies	1997-2002	Federico II University of Naples and Gustave-Roussy Institute / University Paris Sud (France)	Research fellow – Prof. Colao, Prof. Schlumberger and Prof. Baudin. Experience in pituitary diseases, Cushing’s syndrome, endocrine and neuroendocrine tumors and hereditary multiple endocrine neoplasia syndromes
Specialty	1997-2002	Federico II University of Naples. School of Endocrinology	Degree 50/50 cum laude – Prof. Colao
PhD	2003-2007	Federico II University of Naples and Gustave-Roussy Institute / University Paris Sud (France)	PhD on Molecular Oncology and Endocrinology. PhD Coordinator Prof. Vecchio. Supervisor: Prof. Colao and Prof. Schlumberger. Thesis: Clinical and molecular characterization of endocrine and Neuroendocrine tumors.
European Diploma	2002-2003	University Paris Sud (France)	European University Diploma of Clinical Research in Oncology (DUERCC). Supervisor: Prof. Schlumberger. Thesis: « Carcinomes endocrines à grandes cellules peu différenciés: diagnostic et pronostic »
Advanced Course	1999	Second University of Naples, Department of Clinical and Experimental Internal	Emergency Medicine and First Aid

			Medicine "F. Magrassi", Chair of Urgency Medicine and First Aid, responsible Prof. F. Coraggio and Prof. G. Abbate	
4th Postgraduate Course	EFES	2000	European Society of Endocrinology (EFES), Center of Scientific Culture A. Volta, Villa Olmo, Como, responsible Prof A. Spada	Molecular and Cellular Endocrinology
Basic course and advanced course		2000/2001	Italian Society of Ultrasound in Medicine and Biology (SIUMB) at the University Federico II of Naples, responsible Prof. G. Vallone	Practice on Ultrasound
Advanced course		2004	Uppsala University, Sweden, responsible Prof. K. Oberg	Focus on neuroendocrine tumors
Stage		2006	Department of Internal Medicine Section of Endocrinology, Erasmus University Rotterdam (Netherlands), responsible Prof. WW de Herder	Focus on neuroendocrine tumors
Advanced course		2006	Italian Society of Diabetology (SID) at the University Federico II of Naples, responsible Prof. B. Capaldo	Focus on Diagnosis and Therapy of Diabetic Disease and its Complications
Advanced course		2010	European NET Speaker Bureau, Barcelona (Spain)	Focus on neuroendocrine tumors
Licensure 01		1998	Ordine dei Medici di Napoli	Full Registration # NA028437

## Part II – Appointments

### IIA – Academic Appointments

Start	End	Institution	Position
2014	2020	MIUR ASN (Abilitazione Scientifica nazionale) - tornata 2013	Qualification as Associate Professor in the field of Endocrinology, Abilitazione Scientifica Nazionale, Bando 2013 (DD n.161/2013) – sette concorsuale 06/D2. The candidate has all three ministerial criteria
2017	2018	Federico II University of Naples	Researcher of Endocrinology (ricercatore a tempo determinato RTDA, MED13 endocrinologia, sette concorsuale 06/D2)
2018	-	Sapienza University of Rome	Associate Professor of Endocrinology (MED13 endocrinologia, sette

2021	2030	MIUR ASN (Abilitazione Scientifica nazionale) - tornata 2018-2020	concorsuale 06/D2) Qualification as Full Professor in the field of Endocrinology, Abilitazione Scientifica Nazionale, Bando 2018-2020 (D.D. 2175/2018) settore concorsuale 06/D2. The candidate has all three ministerial criteria
------	------	---	---

## IIB – Other Appointments

Start	End	Institution	Position
2002	2003	« Service de Cancerologie Endocrinologique et Médecine Nucléaire » Gustave Roussy Institute, Villejuif, France	« Faisant fonctionne d’interne »
2008	2012	Federico II University of Naples	Post-doctoral research associate
2009	2014	National Cancer Institute Fondazione G. Pascale Napoli	Consultant of endocrinology
2012	2013	Federico II University of Naples	Contract researcher
2013	2013	Federico II University of Naples	Six-month project research - “prestazione occasionale”
2014	2015	Federico II University of Naples	Contract researcher
2015	2015	Federico II University of Naples	Six-month project research - “prestazione occasionale”
2015	2017	National Cancer Institute Fondazione G. Pascale Napoli	Contract researcher
2006	2017	CMP (Centro di Medicina Preventiva), private institute affiliated with SSN, Quarto (NA)	Medical director - “Direttore Sanitario”
2018	2018	Azienda Policlinico Federico II di Napoli	Dirigente Medico – DAI di Gastroenterologia, Endocrinologia e Chirurgia
2021	-	Azienda Ospedaliera Universitaria Sant’Andrea	Dirigente Medico – UOC Medicina Specialistica Endocrina-Metabolica
2011	2021	Frontiers in Cancer Endocrinology	Associate Editor
2022	-	Journal of Endocrinological Investigation	Associate Editor
2012	-	Health Campus Onlus	Co-founder and Treasurer of the Health Campus Onlus for diseases prevention ( <a href="http://www.campussalute.it">www.campussalute.it</a> ).
2012	-	Patient Association “A.I.NET. Vivere la Speranza, amici di Emanuele Cicio”	Member of the National Committee of the National Association of Patients with Neuroendocrine Tumors (AINET).
2021	-	Patient Association “AIMEN Associazione Italiana Neoplasie Endocrine Multiple 1 e 2”	Member of the National Committee of the National Association of Patients with MEN 1 e 2 (AIMEN)

2013	2018	Center of excellence of Neuroendocrine Tumors of Naples, certified by ENETS	Coordinator of the Federico II Unit of Neuroendocrine Tumors which is part of the Center of Neuroendocrine Tumors of Naples, an European center of excellence for Neuroendocrine Tumors, recognized by the ENETS. Coordinator of the Scientific Committee of the Center of Neuroendocrine Tumors of Naples.
2021	-	Center of excellence of Neuroendocrine Tumors of Rome, certified by ENETS	Member of the Center of Neuroendocrine Tumors of Rome Sant'Andrea, an European center of excellence for Neuroendocrine Tumors, recognized by the ENETS
2014	2017	SIE – Italian Society of Endocrinology	Member of the Campania-Molise regional SIE coordination Committee.
2015	2019	SIE – Italian Society of Endocrinology	Member of the Scientific Committee.
2015	-	NIKE project (Neuroendocrine Tumors, Innovation in Knowledge and Education)	Coordinator
2018	2021	ITANET – Italian Society of Neuroendocrine Tumors	Member of the Scientific Commission of the Italian Society of Endocrinology.
2018	-	ENETS – European Society of Neuroendocrine Tumors	Member of the Advisory Board of the European Society of Neuroendocrine Tumors (ENETS).
2019	-	PhD course “Scienze Endocrinologiche” – Department of Experimental Medicine – Sapienza University of Rome	Faculty Member of the PhD course “Scienze Endocrinologiche”

### Part III – Teaching experience

Year	Institution	Lecture/Course
2011/2012	University of Molise	Visiting lecturer of Endocrinology, Faculty of Medicine, School of Medicine, field of neuroendocrine tumors and hereditary multiple endocrine neoplasia syndromes
2012/2013	University of Molise	Visiting lecturer of Endocrinology, Faculty of Medicine, School of Medicine, field of neuroendocrine tumors and hereditary multiple endocrine neoplasia syndromes
2013/2014	University of Molise	Visiting lecturer of Endocrinology, Faculty of Medicine, School of Medicine, field of neuroendocrine tumors and hereditary multiple endocrine neoplasia syndromes
2014/2015	University of Molise	Visiting lecturer of Endocrinology, Faculty of Medicine, School of Medicine, field of neuroendocrine tumors and hereditary

		multiple endocrine neoplasia syndromes
2015/2016	University of Molise	Visiting lecturer of Endocrinology, Faculty of Medicine, School of Medicine, field of neuroendocrine tumors and hereditary multiple endocrine neoplasia syndromes
2016/2017	University of Molise	Visiting lecturer of Endocrinology, Faculty of Medicine, School of Medicine, field of neuroendocrine tumors and hereditary multiple endocrine neoplasia syndromes
2014/2015	Federico II University of Naples	Visiting lecturer of Endocrinology, Faculty of Medicine, School of Medicine, field of neuroendocrine tumors and hereditary multiple endocrine neoplasia syndromes
2015/2016	Federico II University of Naples	Visiting lecturer of Endocrinology, Faculty of Medicine, School of Medicine, field of neuroendocrine tumors and hereditary multiple endocrine neoplasia syndromes
2016/2017	Federico II University of Naples	Visiting lecturer of Endocrinology, Faculty of Medicine, School of Medicine, field of neuroendocrine tumors and hereditary multiple endocrine neoplasia syndromes
2017/2018	Federico II University of Naples	Lecturer of Endocrinology, Faculty of Medicine, School of Medicine
2017/2018	Federico II University of Naples	Lecturer of Endocrinology, Faculty of Medicine, Course of Biomedical Laboratory Technician
2021/2022	Sapienza University of Rome	Lecturer of Endocrinology "Patologia Integrata III" - Medicina e chirurgia 'C' - Roma Azienda Policlinico Umberto I
2020/2021	Sapienza University of Rome	Lecturer of Endocrinology "Patologia Integrata III" - Medicina e chirurgia 'C' - Roma Azienda Policlinico Umberto I
2019/2020	Sapienza University of Rome	Lecturer of Endocrinology "Patologia Integrata III" - Medicina e chirurgia 'C' - Roma Azienda Policlinico Umberto I
2021/2022	Sapienza University of Rome	Lecturer of Endocrinology, Medicina e chirurgia - Roma Azienda Ospedaliera Sant'Andrea
2020/2021	Sapienza University of Rome	Lecturer of Endocrinology, Medicina e chirurgia - Roma Azienda Ospedaliera Sant'Andrea
2021/2022	Sapienza University of Rome	Lecturer of Endocrinology "Patologia Integrata III" - Medicina e chirurgia 'B' - Roma Azienda Policlinico Umberto I
2020/2021	Sapienza University of Rome	Lecturer of Endocrinology "Patologia Integrata III" - Medicina e chirurgia 'B' - Roma Azienda Policlinico Umberto I
2019/2020	Sapienza University of Rome	Lecturer of Endocrinology "Patologia

2021/2022	Sapienza University of Rome	Integrata III” - Medicina e chirurgia 'B' - Roma Azienda Policlinico Umberto I
		Coordinator of the Integrated Course of “Infermieristica dei processi terapeutici ed assistenziali in area medica” and Lecturer of Endocrinology, Infermieristica - Roma Azienda Ospedaliera Sant’Andrea
2020/2021	Sapienza University of Rome	Coordinator of the Integrated Course of “Infermieristica dei processi terapeutici ed assistenziali in area medica” and Lecturer of Endocrinology, Infermieristica - Roma Azienda Ospedaliera Sant’Andrea
2021/2022	Sapienza University of Rome	Coordinator of the Integrated Course of “Fisopatologia dell’alimentazione e delle alterazioni dello stato di nutrizione” and Lecturer of Endocrinology, Scienze, culture e politiche gastronomiche per il benessere - Roma Cittadella Universitaria
2021/2022	Sapienza University of Rome	Lecturer of Endocrinology of Reproduction, Medicina e chirurgia - Roma Azienda Ospedaliera Sant’Andrea
2020/2021	Sapienza University of Rome	Lecturer of “Metodologia Medico-Scientifica Integrata” - Medicina e chirurgia 'B' - Roma Azienda Policlinico Umberto I
2019/2020	Sapienza University of Roma	Lecturer of “Metodologia Medico-Scientifica Integrata” - Medicina e chirurgia 'B' - Roma Azienda Policlinico Umberto I
2017/2018	Federico II University of Naples	Lecturer at the School of Endocrinology
2020/2021	Sapienza University of Rome	Lecturer at the School of Endocrinology
2021/2022	Sapienza University of Rome	Lecturer at the School of Endocrinology
2017	University of Florence	Visiting lecturer, School of Endocrinology, Teaching of neuroendocrine tumors
2012	European Neuroendocrine Tumor Society (ENETS), Berlin	Lecturer at the 3rd ENETS Masterclass in neuroendocrine tumours
2013	Federico II University of Naples	Lecturer at the Master School on Fabry disease

## Part IV

### - Society memberships, Awards, Honors

Member of the following scientific societies: Italian Society of Endocrinology (SIE), Italian Society of Diabetology (SID), Association of Medical Endocrinologists (AME), European Society of Endocrinology (ESE), European Neuroendocrine Association (ENEA), European Neuroendocrine Tumor Society (ENETS), European Network for the Study of Adrenal Tumours (ENS@T), Societe Française d’Endocrinologie (SFE).

Several collaborations with regional, national and international researchers and research groups in the field of endocrine and neuroendocrine tumors and participation in numerous meetings to promote collaborations, research projects and multi-center scientific publications. Participation in several Phase II and III clinical trials in GCP. Training on GCP (Good Clinical Practice).

Reviewer of numerous international peer review journals: *Annals of Oncology*, *British Medical Journal*, *Clinical Endocrinology*, *Endocrine*, *Endocrine-Related Cancer*, *Neuroendocrinology*, *Journal of Neuroendocrinology*, *Journal of Clinical Endocrinology and Metabolism*, *Journal of Endocrinological Investigation*, *Molecular Genetics and Metabolism*, *Nature*, *Annals Oncology*.

Participation in more than 300 courses, workshops, meetings, national and international conferences including ECE (European Congress of Endocrinology), ENETS (European Neuroendocrine Tumor Society), ENEA (European Neuroendocrine Association), Endocrine Society, Pituitary Congress, SIE (Italian Society of Endocrinology), GEP (Pisan days of Endocrinology), GIT (Italian days of Thyroid), AIT (Italian Thyroid Association), AME (Medical Endocrinologists Association), AIOM (Italian Association of Medical Oncology), SID (Italian Society of Diabetology). Speaker or chairman in several national and international courses and congresses from 2001 to today. More than half of the reports presented concerned Neuroendocrine Neoplasms. Participation in numerous advisory boards and investigator meetings in Italy and abroad, related to endocrine and oncological therapies.

Year	Title
2001	Winner of the Scholarship of the Association Leonardo Di Capua, banned by the University Federico II of Naples, Department of Biology and Cellular and Molecular Pathology L. Califano, with the project entitled: Expression and function of dopaminergic and somatostatinergic receptors in tumors of the neuroendocrine system: in vivo and in vitro studies.
2002	Winner of the Euroborsa SIEDP-Grandis award in recognition of his researches on thyroid cancer and ionizing radiation.
2003	Winner of the CONTI prize issued by the Italian Society of Endocrinology (SIE) as best under 30th italian researcher in endocrinology.
2005	Awarded with a Travel Grant from the International Pituitary Congress, for an abstract entitled abstract dal titolo "Sulfur amino acid unbalance in Cushing's disease: Insight in homocysteine and taurine levels in patients with active and cured disease", presented at the congress in San Diego.
2007	Winner of the Italfarmaco award for a research study on the effect of depot long-acting somatostatin analogue octreotide on primary hyperparathyroidism in MEN1 patients.
2008	Winner of the prize of the Association "A.I.NET. Vivere la Speranza, amici di Emanuele Cicio" (BANDO DI CONCORSO NAZIONALE intestato a "Marco Gambacurta") as young researcher in the field of neuroendocrine tumors and MEN syndromes. Montefalco (PG).
2011	Citation in the "Year Book of Endocrinology" for the article "A Decrease of Calcitonin Serum Concentrations Less Than 50 Percent 30 Minutes after Thyroid Surgery Suggests Incomplete C-Cell Tumor Tissue Removal" by Faggiano A et al. <i>J Clin Endocrinol Metab.</i> 2010 Jun 9. [Epub ahead of print] PubMed PMID: 20534767.
2022	Lifetime achievement award issued by the Italian Society of Endocrinology (SIE).

#### **Part V - Funding Information [grants as PI-principal investigator or I-investigator]**

Year	Title	Program	Grant value
2008	Innovations in diagnosis, prognosis and therapy of neuroendocrine tumors.	Ministry for Instruction, University and Research (MIUR) PRIN - Investigator (assegnista di ricerca su fondi del progetto)	487.286,00 € (total grant)
2012-2013	Ricerca e sviluppo di farmaci biologici innovativi in oncologia: produzione di frammenti di anticorpi monoclonali peghilati e di miRNA ad uso terapeutico e/o diagnostico	Cocopro del Dipartimento di Medicina Clinica e Chirurgia, Università Federico II di Napoli, su progetto PON Ricerca e Competitività 2007-2013	12.000,00 €
2014-2015	Smart health – cluster osdh – smart fse staywell	Cocopro del Dipartimento di Medicina Clinica e Chirurgia, Università Federico II di Napoli, su progetto finanziato nell’ambito del Programma Operativo Nazionale R&C 2007-2013	19.400,00 €
2015-2017	Caratterizzazione molecolare, diagnosi e cura delle neoplasie tiroidee	Cocopro dell’Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Giovanni Pascale di Napoli	46.000,00 €
2017	From bed to benchside: unAnglIng The molecular mechanisms of disease progressIoN in neuroenDocRine nEoplAsMS.	Ministry for Instruction, University and Research (MIUR) PRIN – Unit Coordinator	803.522,00 € (total grant)
2020	Tumour educated platelets as new prognostic factors in neuroendocrine neoplasms: TEP NEN study	Bandi di Ricerca Ateneo Sapienza	10.000,00 €
2021	Il ruolo degli interferenti endocrini nel diabete mellito	Sapienza SEED PNR 2022	10.000,00 €
2022	Stato di salute dell'osso nei pazienti affetti da Tumori Neuroendocrini	Sapienza SEED PNR 2022	10.000,00 €
2022	PE6 - Diagnostica e terapie innovative nella medicina di precisione	PNRR Partenariati estesi – HEAL Italia – PE6 Spoke 4	1.507.655,53 € (total grant)

## Part VI – Research Activities

Keywords	Brief Description
Neuroendocrine tumors	Clinical and translational research: epidemiology, diagnosis, differential diagnosis, new diagnostic tracers, clinical-pathological prognostic factors, metabolic abnormalities, molecular pathways, genetic and environmental risk factors, genetic tumors (MEN1, VHL, NF1, STB), genetic screening,
Endocrine tumors	
Hereditary multiple	



endocrine neoplasia syndromes	polymorphisms, therapy (new drugs, new combination schemes, new assays, therapy sequences), evaluation of the response to therapies.
Diabetes and Cancer	
Pituitary diseases	

He dedicated his early carrier to pituitary tumors and in particular to Cushing's disease by publishing many papers on JCEM and other well recognized journals of endocrinology. Since the time of his experience at the Gustave Roussy Institute in France, he focused on endocrine tumors and in particular on neuroendocrine neoplasms and hereditary neoplastic syndromes (i.e. MEN1, MEN2, paragangliomatosis) by elaborating many research projects and publishing several papers on journals of endocrinology and oncology. He also investigated thyroid tumors (both medullary and differentiated types), adrenal tumors, hyperparathyroidism, as well as systemic disorders such as diabetes mellitus and Fabry disease, always publishing his research in well recognized ISI journals. Recently, he developed some research projects and published original and review articles in the field of andrology and in particular on infertility, erectile dysfunction and sexual health.

### Part VII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	282	Scopus, Web of Science, Pubmed	1998	2023
Papers [international] last 10 yrs	183	Scopus, Web of Science, Pubmed	2013	2023
Papers [national]	3	Scopus	2007	2011
Books [scientific]	6	Editions: Alleanza contro il Cancro, In Tech, AIOM, Springer International	2009	2021
Books [teaching]	10	Editions: Club delle U.E.C., Piccin Nuova Libreria, Minerva Medica, Società Editrice Universo, Idelson-Gnocchi, SICS Editore Srl	2007	2017

	Scopus, Web of Science, Pubmed, Scijournal.org
Total Impact factor	1197
Average Impact factor	4,24
Total Impact factor last 10 years	902,2
Average Impact factor last 10 years	4,93
Papers published as first author, last author or corresponding author	107 (38%)
Total Citations	8831
Average Citations per Product	31,3

Total Citations last 10 years	6378
Average Citations per Product last 10 years	34,8
Hirsch (H) index	49
H index last 10 years	31
Normalized H index§	49/26=1,9

§ H index divided by the academic seniority (defined from graduation in MD)

## Part VIII – Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF, citations (from Scopus, Web of Science), press/media release (if any).

- 1) Marotta V, Sciammarella C, Colao A, Faggiano A. Application of molecular biology of differentiated thyroid cancer for clinical prognostication. *Endocr Relat Cancer*. 2016 Nov;23(11):R499-R515. doi: 10.1530/ERC-16-0372. Epub 2016 Aug 30. PMID: 27578827. Impact Factor: 5,267 Citations: 32
- 2) Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD; Knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. *Endocr Relat Cancer*. 2014 May 6;21(3):R153-63. doi:10.1530/ERC-13-0125. PMID: 24322304. Impact Factor: 4,805 Citations: 221
- 3) Faggiano A, Lo Calzo F, Pizza G, Modica R, Colao A. The safety of available treatments options for neuroendocrine tumors. *Expert Opin Drug Saf*. 2017 Oct;16(10):1149-1161. doi: 10.1080/14740338.2017.1354984. Epub 2017 Jul 20. PMID: 28705090. Impact Factor: 3,156 Citations: 20
- 4) Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology*. 2018 Aug;155(2):479-489.e7. doi:10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13. PMID: 29655834. Impact Factor: 19,809 Citations: 51
- 5) Altieri B, Barrea L, Modica R, Muscogiuri G, Savastano S, Colao A, Faggiano A. Nutrition and neuroendocrine tumors: An update of the literature. *Rev Endocr Metab Disord*. 2018 Jun;19(2):159-167. doi: 10.1007/s11154-018-9466-z. PMID:30267297. Impact Factor: 5,516 Citations: 34
- 6) Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, ChiofaloMG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center,

open-label, phase II, proof-of-concept study. *Endocrine*. 2018 Oct;62(1):46-56. doi: 10.1007/s12020-018-1583-7. Epub 2018 Mar 23. PMID: 29572709. Impact Factor: 3,296 Citations: 14

- 7) Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. *Endocrine*. 2014 Sep;47(1):177-82. doi: 10.1007/s12020-013-0130-9. Epub 2014 Jan 3. PMID: 24385266. Impact Factor: 3,878 Citations: 90
- 8) Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. *Endocr Relat Cancer*. 2018 Jan;25(1):R11-R29. doi: 10.1530/ERC-17-0269. Epub 2017 Oct 24. PMID: 29066503. Impact Factor: 4,774 Citations: 90
- 9) Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, de la Fouchardière C, Valdes N, Riccardi F, Do Cao C, Bertherat J, Goichot B, Beuschlein F, Drui D, Canu L, Niccoli P, Laboureau S, Tabarin A, Leboulleux S, Calsina B, Libé R, Faggiano A, Schlumberger M, Borson-Chazot F, Mannelli M, Gimenez-Roqueplo AP, Caron P, Timmers HJLM, Fassnacht M, Robledo M, Borget I, Baudin E; European Network for the Study of Adrenal Tumors (ENS@T). Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. *J Clin Endocrinol Metab*. 2019 Jun 1;104(6):2367-2374. doi: 10.1210/jc.2018-01968. PMID: 30715419. Impact Factor: 5,399 Citations: 82
- 10) Marotta V, Sciammarella C, Chiofalo MG, Gambardella C, Bellevicine C, Grasso M, Conzo G, Docimo G, Botti G, Losito S, Troncone G, De Palma M, Giacomelli L, Pezzullo L, Colao A, Faggiano A. Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. *Endocr Relat Cancer*. 2017 Sep;24(9):485-493. doi: 10.1530/ERC-17-0085. Epub 2017 Jul 10. PubMed PMID: 28696209. Impact Factor: 5.331. Citations: 38
- 11) Faggiano A, Modica R, Lo Calzo F, Camera L, Napolitano V, Altieri B, de Cicco F, Bottiglieri F, Sesti F, Badalamenti G, Isidori AM, Colao A. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. *J Clin Endocrinol Metab*. 2020 Jan 1;105(1):78-84. doi:10.1210/clinem/dgz007. PMID: 31586182. Impact Factor: 5,958 Citations: 31
- 12) Faggiano A, Mazzilli R, Natalicchio A, Adinolfi V, Argentiero A, Danesi R, D'Oronzo S, Fogli S, Gallo M, Giuffrida D, Gori S, Montagnani M, Ragni A, Renzelli V, Russo A, Silvestris N, Franchina T, Tuveri E, Cinieri S, Colao A, Giorgino F, Zatelli MC; Oncological Endocrinology research group of the Italian Society of Endocrinology. Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. *Crit Rev Oncol Hematol*. 2022 Dec;180:103826. doi: 10.1016/j.critrevonc.2022.103826. Epub 2022 Sep 30. PMID: 36191821. Impact Factor: 6,625 Citations: 2
- 13) Lamberti G\*, Faggiano A\*, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, Gelsomino F, De Divitiis C, Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D.

Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. J Clin Endocrinol Metab. 2020 Jan 1;105(1):194-200. doi: 10.1210/clinem/dgz035. PMID:31545377. \*co-first author Impact Factor: 5,958 Citations: 28

- 14) Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, de Herder WW, Pavel M, Faggiano A, Kos-Kudla B, Öberg K, Krejs GJ, Grande E, Niederle B, Sundin A. ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. J Neuroendocrinol. 2022 Mar;34(3):e13044. doi:10.1111/jne.13044. Epub 2021 Oct 25. PMID: 34693574; PMCID: PMC9286653. Impact Factor: 3,87 Citations: 9
- 15) Olana S, Mazzilli R, Salerno G, Zamponi V, Tarsitano MG, Simmaco M, Paoli D, Faggiano A. 4BNT162b2 mRNA COVID-19 vaccine and semen: What do we know? Andrology. 2022 Sep;10(6):1023-1029. doi: 10.1111/andr.13199. Epub 2022 Jun 8. PMID: 35647664; PMCID: PMC9348225. Impact Factor: 4,456 Citations: 12
- 16) Puliani G, Di Vito V, Feola T, Sesti F, Centello R, Pandozzi C, Tarsitano MG, Verrico M, Lenzi A, Isidori AM, Giannetta E, Faggiano A. NETest: A Systematic Review Focusing on the Prognostic and Predictive Role. Neuroendocrinology. 2022;112(6):523-536. doi: 10.1159/000518873. Epub 2021 Aug 5. PMID: 34515175. Impact Factor: 5,135 Citations: 13

First author, last author or corresponding author in 12/16.

DICHIARAZIONI SOSTITUTIVE DI CERTIFICAZIONE E DELL'ATTO DI NOTORIETA' AI SENSI DEGLI ARTT. 46 E 47 DEL D.P.R. 28 DICEMBRE 2000, N. 445.

Il sottoscritto Faggiano Antongiulio nato a Napoli prov. Napoli il 15/07/1973 e residente in Roma Via Goffredo Mameli 30

consapevole delle sanzioni penali nel caso di dichiarazioni non veritiere, di formazione o uso di atti falsi, richiamate dall'art. 76 del D.P.R. 28 dicembre 2000 n. 445,

DICHIARA:

di essere in possesso di tutti i titoli riportati nel Curriculum Vitae e che quanto affermato nel Curriculum Vitae corrisponde a verità.

Luogo e data Roma, 20/07/2023



Firma

**Si allega l'elenco completo delle pubblicazioni prodotte nell'arco temporale dell'attività accademica (allegato 1).**

## Allegato 1

### Publicazioni scientifiche indicizzate in Pubmed su riviste internazionali con Peer-Review

---

1. de Mestier L, Resche-Rigon M, Dromain C, Lamarca A, La Salvia A, de Baker L, Fehrenbach U, Pusceddu S, Colao A, Borbath I, de Haas R, Rinzivillo M, Zerbi A, Funicelli L, de Herder WW, Selberherr A, Wagner AD, Manoharan P, De Cima A, Lybaert W, Jann H, Prinzi N, **Faggiano A**, Annet L, Walenkamp A, Panzuto F, Pedicini V, Pitoni MG, Siebenhuener A, Mayerhoefer ME, Ruszniewski P, Vullierme MP. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST. *J Neuroendocrinol*. 2023 Jun;35(6):e13311. doi:10.1111/jne.13311. Epub 2023 Jun 21. PMID: 37345276.
2. **Faggiano A**, Giannetta E, Modica R, Albertelli M, Barba L, Dolce P, Motta C, Deiana MG, Martinelli R, Zamponi V, Sesti F, Patti L, Scavuzzo F, Colao A, Monti S. Calcium-stimulated calcitonin test for the diagnosis of medullary thyroid cancer: results of a multicenter study and comparison between different assays. *Minerva Endocrinol (Torino)*. 2023 Jun 16. doi: 10.23736/S2724-6507.23.04017-4. Epub ahead of print. PMID: 37326573.
3. Natalicchio A, Montagnani M, Gallo M, Marrano N, **Faggiano A**, Zatelli MC, Mazzilli R, Argentiero A, Danesi R, D'Oronzo S, Fogli S, Giuffrida D, Gori S, Ragni A, Renzelli V, Russo A, Franchina T, Tuveri E, Sciacca L, Monami M, Cirino G, Di Cianni G, Colao A, Avogaro A, Cinieri S, Silvestris N, Giorgino F. MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocrinology (SIE)/Italian Society of Pharmacology (SIF) multidisciplinary critical view. *ESMO Open*. 2023 Jun;8(3):101573. doi:10.1016/j.esmoop.2023.101573. Epub 2023 May 31. PMID: 37263082; PMCID: PMC10245125.
4. Salerno G, Borro M, Visco V, Olana S, Gargano F, Raffa S, Zamponi V, Mancini C, **Faggiano A**, Simmaco M, Mazzilli R. The Impact of Non-Andrological Medications on Semen Characteristics, Oxidative Stress and Inflammatory Parameters. *Medicina (Kaunas)*. 2023 May 8;59(5):903. doi: 10.3390/medicina59050903. PMID: 37241135; PMCID: PMC10222916.
5. Defeudis G, Mazzilli R, Benvenuto D, Ciccozzi M, Di Tommaso AM, **Faggiano A**, Tuccinardi D, Watanabe M, Manfrini S, Khazrai YM. Women with type 1 diabetes gain more weight during pregnancy compared to age matched healthy women despite a healthier diet: a prospective case-control observational study. *Hormones (Athens)*. 2023 May 26. doi: 10.1007/s42000-023-00454-6. Epub ahead of print. PMID: 37231315.
6. Laffi A, Lania AGA, Ragni A, Di Vito V, Liccardi A, Rubino M, Sesti F, Colao A, **Faggiano A**, On Behalf Of The Nike Group. Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs. *Cancers (Basel)*. 2023 Apr 8;15(8):2202. doi: 10.3390/cancers15082202. PMID: 37190131; PMCID: PMC10137004.
7. Fanciulli G, Modica R, La Salvia A, Grossrubatscher EM, Florio T, Ferraù F, Veresani A, Russo F, Colao A, **Faggiano A**. Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials? *Front Endocrinol (Lausanne)*. 2023 Apr 20;14:1145926. doi: 10.3389/fendo.2023.1145926. PMID: 37152939; PMCID: PMC10157225.

8. Magi L, Marasco M, Rinzivillo M, **Faggiano A**, Panzuto F. Management of Functional Pancreatic Neuroendocrine Neoplasms. *Curr Treat Options Oncol*. 2023 Jul;24(7):725-741. doi: 10.1007/s11864-023-01085-0. Epub 2023 Apr 27. PMID: 37103745; PMCID: PMC10272249.
9. Camera L, Boccadifuoco F, Modica R, Messerini L, **Faggiano A**, Romeo V, Gaudieri V, Colao A, Maurea S, Brunetti A; European Neuroendocrine Tumor Society (ENETS) of Naples. Gastrinomas and non-functioning pancreatic endocrine tumors in multiple endocrine neoplasia syndrome type-1 (MEN-1). *Endocrine*. 2023 Apr 26. doi: 10.1007/s12020-023-03373-z. Epub ahead of print. PMID: 37099246.
10. La Salvia A, Modica R, Rossi RE, Spada F, Rinzivillo M, Panzuto F, **Faggiano A**, Cinieri S, Fazio N. Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists. *Cancer Treat Rev*. 2023 Jun;117:102560. doi: 10.1016/j.ctrv.2023.102560. Epub 2023 Apr 17. PMID: 37088017.
11. Modica R, Altieri B, D'Aniello F, Benevento E, Cannavale G, Minotta R, Liccardi A, Colao A, **Faggiano A**. Vitamin D and Bone Metabolism in Adult Patients with Neurofibromatosis Type 1. *Metabolites*. 2023 Feb 9;13(2):255. doi:10.3390/metabo13020255. PMID: 36837874; PMCID: PMC9966600.
12. Altieri B, La Salvia A, Modica R, Marciello F, Mercier O, Filosso PL, de Latour BR, Giuffrida D, Campione S, Guggino G, Fadel E, Papotti M, Colao A, Scoazec JY, Baudin E, **Faggiano A**. Recurrence-Free Survival in Early and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Tumor Resection. *J Pers Med*. 2023 Feb 15;13(2):330. doi: 10.3390/jpm13020330. PMID: 36836564; PMCID: PMC9965978.
13. Vitale G, Carra S, Alessi Y, Campolo F, Pandozzi C, Zanata I, Colao A, **Faggiano A**, On Behalf Of The Nike Group. Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies. *Int J Mol Sci*. 2023 Feb 10;24(4):3610. doi:10.3390/ijms24043610. PMID: 36835022; PMCID: PMC9961914.
14. Defeudis G, Mazzilli R, Scandurra C, Di Tommaso AM, Cimadomo D, Strollo R, **Faggiano A**, Migliaccio S, Napoli N. Diabetes and erectile dysfunction: The relationships with health literacy, treatment adherence, unrealistic optimism, and glycaemic control. *Diabetes Metab Res Rev*. 2023 Jul;39(5):e3629. doi: 10.1002/dmrr.3629. Epub 2023 Mar 3. PMID: 36823962.
15. Mazzilli R, Zamponi V, Mangini F, Olana S, Defeudis G, **Faggiano A**, Gianfrilli D. The effects of non-andrological medications on erectile dysfunction: a large single-center retrospective study. *J Endocrinol Invest*. 202 Jul;46(7):1465-1473. doi: 10.1007/s40618-023-02011-9. Epub 2023 Jan 19. PMID: 36656432; PMCID: PMC9850328.
16. Malandrino P, Mazzilli R, Puliani G, Di Molfetta S, Pugliese G, Olana S, Colao AM, **Faggiano A**, On Behalf Of The Nike Group. The Effects of Radioligand Therapy on Quality of Life and Sexual Function in Patients with Neuroendocrine Neoplasms. *Cancers (Basel)*. 2022 Dec 24;15(1):115. doi: 10.3390/cancers15010115. PMID: 36612112; PMCID: PMC9817532.
17. Arrivi G, Verrico M, Roberto M, Barchiesi G, **Faggiano A**, Marchetti P, Mazzuca F, Tomao S. Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis. *Cancer Manag Res*. 2022 Dec 21;14:3507-3523. doi: 10.2147/CMAR.S372776. PMID: 36575665; PMCID: PMC9790144.

18. Sesti F, Puliani G, Feola T, Campolo F, Sciarra F, Hasenmajer V, Lenzi A, **Faggiano A**, Isidori AM, Venneri MA, Giannetta E. Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis. *Endocrine*. 2023 Apr;80(1):221-230. doi: 10.1007/s12020-022-03257-8. Epub 2022 Dec 12. PMID: 36509928.
19. Zamponi V, Defeudis G, Federico F, **Faggiano A**, Mazzilli R. Erectile Dysfunction Severity: The Role of Glycometabolic Compensation and Antihyperglycemic Drugs. *J Clin Med*. 2022 Dec 5;11(23):7214. doi:10.3390/jcm11237214. PMID: 36498788; PMCID: PMC9740756.
20. Prosperi D, Gentiloni Silveri G, Panzuto F, **Faggiano A**, Russo VM, Caruso D, Polici M, Lauri C, Filice A, Laghi A, Signore A. Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update. *J Clin Med*. 2022 Nov 18;11(22):6836. doi: 10.3390/jcm11226836. PMID: 36431313; PMCID: PMC9694730.
21. Modica R, La Salvia A, Liccardi A, Cannavale G, Minotta R, Benevento E, **Faggiano A**, Colao A. Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target. *Metabolites*. 2022 Nov 2;12(11):1057. doi: 10.3390/metabo12111057. PMID: 36355141; PMCID: PMC9692415.
22. Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Ragni A, Zanata I, Colao A, **Faggiano A**. What Lies behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature. *J Pers Med*. 2022 Sep 21;12(10):1553. doi: 10.3390/jpm12101553. PMID: 36294693; PMCID: PMC9604936.
23. La Salvia A, Carletti R, Verrico M, Feola T, Puliani G, Bassi M, Sesti F, Pernazza A, Mazzilli R, Lamberti G, Siciliani A, Mancini M, Manai C, Venuta F, Ibrahim M, Tomao S, D'Amati G, Di Gioia C, Giannetta E, Cappuzzo F, **Faggiano A**. Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma. *J Clin Med*. 2022 Oct 9;11(19):5958. doi:10.3390/jcm11195958. PMID: 36233825; PMCID:PMC9570740.
24. Ruggeri RM, Benevento E, De Cicco F, Fazzalari B, Guadagno E, Hasballa I, Tarsitano MG, Isidori AM, Colao A, **Faggiano A**; NIKE Group. Correction to: Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. *J Endocrinol Invest*. 2023 Jan;46(1):203. doi: 10.1007/s40618-022-01924-1. Erratum for: *J Endocrinol Invest*. 2022 Aug 30;: PMID: 36205909.
25. **Faggiano A**, Mazzilli R, Natalicchio A, Adinolfi V, Argentiero A, Danesi R, D'Oronzo S, Fogli S, Gallo M, Giuffrida D, Gori S, Montagnani M, Ragni A, Renzelli V, Russo A, Silvestris N, Franchina T, Tuveri E, Cinieri S, Colao A, Giorgino F, Zatelli MC; Oncological Endocrinology research group of the Italian Society of Endocrinology. Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. *Crit Rev Oncol Hematol*. 2022 Dec;180:103826. doi: 10.1016/j.critrevonc.2022.103826. Epub 2022 Sep 30. PMID: 36191821.
26. Muscogiuri G, Barrea L, Cantone MC, Guarnotta V, Mazzilli R, Verde L, Vetrani C, Colao A, **Faggiano A**; NIKE. Neuroendocrine Tumors: A Comprehensive Review on Nutritional



Approaches. *Cancers (Basel)*. 2022 Sep 10;14(18):4402. doi:10.3390/cancers14184402. PMID: 36139562; PMCID: PMC9496842.

27. Ferolla P, Berruti A, Spada F, Brizzi MP, Ibrahim T, Marconcini R, Giuffrida D, Amoroso V, La Salvia A, Vaccaro V, **Faggiano A**, Colao A, Volante M, Ghizzoni S, Mazzanti P, Houchard A, Fazio N. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. *Neuroendocrinology*. 2023;113(3):332-342. doi: 10.1159/000526811. Epub 2022 Aug 31. PMID: 36044870.
28. Fanciulli G, Modica R, La Salvia A, Campolo F, Florio T, Mikovic N, Plebani A, Di Vito V, Colao A, **Faggiano A**; NIKE Group. Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells? *Cancers (Basel)*. 2022 Aug 18;14(16):3991. doi: 10.3390/cancers14163991. PMID: 36010987; PMCID: PMC9406675.
29. Olana S, Mazzilli R, Santino I, Martinelli D, Zamponi V, Macera M, Salerno G, Mazzilli F, **Faggiano A**, Gianfrilli D. Sperm culture and bacterial susceptibility to antibiotics in a large andrological population: prevalence and impact on seminal parameters. *Int Microbiol*. 2023 Jan;26(1):69-79. doi:10.1007/s10123-022-00273-6. Epub 2022 Aug 24. PMID: 36001166; PMCID: PMC9810678.
30. Mazzilli R, Medenica S, Di Tommaso AM, Fabozzi G, Zamponi V, Cimadomo D, Rienzi L, Ubaldi FM, Watanabe M, **Faggiano A**, La Vignera S, Defeudis G. The role of thyroid function in female and male infertility: a narrative review. *J Endocrinol Invest*. 2023 Jan;46(1):15-26. doi: 10.1007/s40618-022-01883-7. Epub 2022 Aug 9. PMID: 35945393; PMCID: PMC9829629.
31. Zamponi V, La Salvia A, Tarsitano MG, Mikovic N, Rinzivillo M, Panzuto F, Giannetta E, **Faggiano A**, Mazzilli R. Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function. *J Clin Med*. 2022 Jul 8;11(14):3983. doi: 10.3390/jcm11143983. PMID: 35887747; PMCID: PMC9324753.
32. Modica R, Scandurra C, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, Di Vito V, Giannetta E, Isidori AM, Lenzi A, **Faggiano A**, Colao A. Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study. *J Endocrinol Invest*. 2022 Nov;45(11):2193-2200. doi:10.1007/s40618-022-01872-w. Epub 2022 Jul 22. PMID: 35867331; PMCID: PMC9305061.
33. Defeudis G, Di Tommaso AM, Di Rosa C, Cimadomo D, Khazrai YM, **Faggiano A**, Cincione RI, Napoli N, Mazzilli R. The Role of Antihyperglycemic Drugs and Diet on Erectile Function: Results from a Perspective Study on a Population with Prediabetes and Diabetes. *J Clin Med*. 2022 Jun 13;11(12):3382. doi:10.3390/jcm11123382. PMID: 35743453; PMCID: PMC9224931.
34. Olana S, Mazzilli R, Salerno G, Zamponi V, Tarsitano MG, Simmaco M, Paoli D, **Faggiano A**. 4BNT162b2 mRNA COVID-19 vaccine and semen: What do we know? *Andrology*. 2022 Sep;10(6):1023-1029. doi:10.1111/andr.13199. Epub 2022 Jun 8. PMID: 35647664; PMCID: PMC9348225.
35. Medenica S, Spoltore ME, Ormazabal P, Marina LV, Sojat AS, **Faggiano A**, Gnessi L, Mazzilli R, Watanabe M. Female infertility in the era of obesity: The clash of two pandemics or

inevitable consequence? *Clin Endocrinol (Oxf)*. 2023 Feb;98(2):141-152. doi: 10.1111/cen.14785. Epub 2022 Jun 7. PMID: 35644933; PMCID: PMC10084349.

36. Grillo F, Albertelli M, Malandrino P, Dotto A, Pizza G, Cittadini G, Colao A, **Faggiano A**. Prognostic Effect of Lymph Node Metastases and Mesenteric Deposits in Neuroendocrine Tumors of the Small Bowel. *J Clin Endocrinol Metab*. 2022 Nov 25;107(12):3209-3221. doi: 10.1210/clinem/dgac326. PMID: 35639999.
37. Giuliani C, Sciacca L, Biase ND, Tumminia A, Milluzzo A, **Faggiano A**, Romana Amorosi F, Convertino A, Bitterman O, Festa C, Napoli A. Gestational Diabetes Mellitus pregnancy by pregnancy: early, late and nonrecurrent GDM. *Diabetes Res Clin Pract*. 2022 Jun;188:109911. doi: 10.1016/j.diabres.2022.109911. Epub 2022 May 7. PMID: 35537521.
38. Defeudis G, Mazzilli R, Di Tommaso AM, Zamponi V, Carlomagno F, Tuccinardi D, Watanabe M, **Faggiano A**, Gianfrilli D. Effects of diet and antihyperglycemic drugs on erectile dysfunction: A systematic review. *Andrology*. 2023 Feb;11(2):282-294. doi: 10.1111/andr.13192. Epub 2022 May 13. PMID: 35485604; PMCID: PMC10084359.
39. Feola T, Centello R, Sesti F, Puliani G, Verrico M, Di Vito V, Di Gioia C, Bagni O, Pisegna S, Lenzi A, Isidori AM, Giannetta E, **Faggiano A**. The Strange Case of a Pancreatic Neuroendocrine Carcinoma With Low Proliferation Index and Atypical Clinical Behavior. *Pancreas*. 2022 Feb 1;51(2):e25-e27. doi: 10.1097/MPA.0000000000001999. PMID: 35404907.
40. Mazzilli R, Zamponi V, Olana S, Mikovic N, Cimadomo D, Defeudis G, **Faggiano A**. Erectile dysfunction as a marker of endocrine and glycemic disorders. *J Endocrinol Invest*. 2022 Aug;45(8):1527-1534. doi: 10.1007/s40618-022-01788-5. Epub 2022 Apr 2. PMID: 35366160; PMCID: PMC9270283.
41. La Salvia A, Persano I, Siciliani A, Verrico M, Bassi M, Modica R, Audisio A, Zanata I, Trabalza Marinucci B, Trevisi E, Puliani G, Rinzivillo M, Parlagraeco E, Baldelli R, Feola T, Sesti F, Razzore P, Mazzilli R, Mancini M, Panzuto F, Volante M, Giannetta E, Romero C, Appetecchia M, Isidori A, Venuta F, Ambrosio MR, Zatelli MC, Ibrahim M, Colao A, Brizzi MP, García-Carbonero R, **Faggiano A**. Prognostic significance of laterality in lung neuroendocrine tumors. *Endocrine*. 2022 Jun;76(3):733-746. doi: 10.1007/s12020-022-03015-w. Epub 2022 Mar 18. PMID: 35301675; PMCID: PMC9156515.
42. Ruggeri RM, Altieri B, Grossrubatcher E, Minotta R, Tarsitano MG, Zamponi V, Isidori AM, **Faggiano A**, Colao A; NIKE Group. Sex differences in carcinoid syndrome: A gap to be closed. *Rev Endocr Metab Disord*. 2022 Jun;23(3):659-669. doi: 10.1007/s11154-022-09719-8. Epub 2022 Mar 16. PMID: 35292889.
43. Muscogiuri G, Zanata I, Barrea L, Cozzolino A, Filice E, Messina E, Colao A, **Faggiano A**; on behalf of NIKE Group. A practical nutritional guideline to manage neuroendocrine neoplasms through chronotype and sleep. *Crit Rev Food Sci Nutr*. 2022 Mar 14:1-18. doi: 10.1080/10408398.2022.2047882. Epub ahead of print. PMID: 35285728.
44. Di Molfetta S, Feola T, Fanciulli G, Florio T, Colao A, **Faggiano A**, Nike Group. Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver? *J Clin Med*. 2022 Feb 16;11(4):1019. doi: 10.3390/jcm11041019. PMID: 35207291; PMCID: PMC8876213.

45. Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, Panzuto F, Baldari S, Grana CM, Campana D, Davì MV, Giuffrida D, Zatelli MC, Partelli S, Razzore P, Marconcini R, Massironi S, Gelsomino F, **Faggiano A**, Giannetta E, Bajetta E, Grimaldi F, Cives M, Cirillo F, Perfetti V, Corti F, Ricci C, Giacomelli L, Porcu L, Di Maio M, Seregini E, Maccauro M, Lastoria S, Bongiovanni A, Versari A, Persano I, Rinzivillo M, Pignata SA, Rocca PA, Lamberti G, Cingarlini S, Puliafito I, Ambrosio MR, Zanata I, Bracigliano A, Severi S, Spada F, Andreasi V, Modica R, Scalorbi F, Milione M, Sabella G, Coppa J, Casadei R, Di Bartolomeo M, Falconi M, de Braud F. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. *JAMA Netw Open*. 2022 Feb 1;5(2):e220290. doi: 10.1001/jamanetworkopen.2022.0290. Erratum in: *JAMA Netw Open*. 2022 Mar 1;5(3):e227517. PMID: 35201309; PMCID: PMC8874344.
46. Marchini F, Caputo A, Langher V, Giuliani C, Convertino A, Mazzilli R, **Faggiano A**, Napoli A. Understanding care relationships in diabetes practice: A psychodynamic interview-based exploratory study. *PLoS One*. 2022 Feb 17;17(2):e0263226. doi: 10.1371/journal.pone.0263226. PMID: 35176064; PMCID: PMC8853562.
47. Puliani G, Sesti F, Anastasi E, Verrico M, Tarsitano MG, Feola T, Campolo F, Di Gioia CRT, Venneri MA, Angeloni A, Appetecchia M, Lenzi A, Isidori AM, **Faggiano A**, Giannetta E; Nettare Unit. Angiogenic factors as prognostic markers in neuroendocrine neoplasms. *Endocrine*. 2022 Apr;76(1):208-217. doi: 10.1007/s12020-021-02942-4. Epub 2022 Jan 28. PMID: 35088292.
48. Feola T, Puliani G, Sesti F, Modica R, Centello R, Minotta R, Cannavale G, Di Meglio S, Di Vito V, Lauretta R, Appetecchia M, Colao A, Lenzi A, Isidori AM, **Faggiano A**, Giannetta E. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. *J Endocrinol Invest*. 2022 Apr;45(4):849-857. doi: 10.1007/s40618-021-01715-0. Epub 2022 Jan 18. PMID: 35040099.
49. Natalicchio A, **Faggiano A**, Zatelli MC, Argentiero A, D'Oronzo S, Marrano N, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, Ferrari P, Gori S, Morviducci L, Russo A, Tuveri E, Montagnani M, Gallo M, Silvestris N, Giorgino F. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. *Crit Rev Oncol Hematol*. 2022 Jan;169:103572. doi: 10.1016/j.critrevonc.2021.103572. Epub 2021 Dec 22. PMID: 34954047.
50. Altieri B, Lalli E, **Faggiano A**. Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy. *Minerva Endocrinol (Torino)*. 2022 Jun;47(2):203-214. doi: 10.23736/S2724-6507.21.03601-0. Epub 2021 Dec 9. PMID: 34881855.
51. Canu L, Puglisi S, Berchiolla P, De Filipo G, Brignardello F, Schiavi F, Ferrara AM, Zovato S, Luconi M, Pia A, Appetecchia M, Arvat E, Letizia C, Maccario M, Parasiliti-Caprino M, Altieri B, **Faggiano A**, Modica R, Morelli V, Arosio M, Verga U, Pellegrino M, Petramala L, Concistrè A, Razzore P, Ercolino T, Rapizzi E, Maggi M, Stigliano A, Burrello J, Terzolo M, Opocher G, Mannelli M, Reimondo G. A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. *Cancers*

(Basel). 2021 Nov 20;13(22):5831. doi: 10.3390/cancers13225831. PMID: 34830985; PMCID: PMC8616182.

52. Capodanno Y, Altieri B, Elders R, Colao A, **Faggiano A**, Schrader J. Canine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies. *Transl Oncol*. 2022 Jan;15(1):101269. doi: 10.1016/j.tranon.2021.101269. Epub 2021 Nov 15. PMID: 34794032; PMCID: PMC8605301.
53. Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, de Herder WW, Pavel M, **Faggiano A**, Kos-Kudla B, Öberg K, Krejs GJ, Grande E, Niederle B, Sundin A. ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. *J Neuroendocrinol*. 2022 Mar;34(3):e13044. doi: 10.1111/jne.13044. Epub 2021 Oct 25. PMID: 34693574; PMCID: PMC9286653.
54. La Salvia A, Sesti F, Grinzato C, Mazzilli R, Tarsitano MG, Giannetta E, **Faggiano A**. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review. *Pharmaceuticals (Basel)*. 2021 Oct 12;14(10):1039. doi: 10.3390/ph14101039. PMID: 34681263; PMCID: PMC8538402.
55. Altieri B, Barrea L, Modica R, Bottiglieri F, de Cicco F, Muscogiuri G, Circelli L, Savarese G, Di Somma C, Savastano S, Colao A, **Faggiano A**. Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. *Endocrine*. 2022 Feb;75(2):623-634. doi: 10.1007/s12020-021-02869-w. Epub 2021 Sep 17. PMID: 34533768.
56. Puliani G, Di Vito V, Feola T, Sesti F, Centello R, Pandozzi C, Tarsitano MG, Verrico M, Lenzi A, Isidori AM, Giannetta E, **Faggiano A**. NETest: A Systematic Review Focusing on the Prognostic and Predictive Role. *Neuroendocrinology*. 2022;112(6):523-536. doi: 10.1159/000518873. Epub 2021 Aug 5. PMID: 34515175.
57. Defeudis G, Mazzilli R, Tenuta M, Rossini G, Zamponi V, Olana S, **Faggiano A**, Pozzilli P, Isidori AM, Gianfrilli D. Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. *Diabetes Metab Res Rev*. 2022 Feb;38(2):e3494. doi: 10.1002/dmrr.3494. Epub 2021 Sep 21. PMID: 34514697; PMCID: PMC9286480.
58. Mazzilli R, Zamponi V, **Faggiano A**. Letter to the editor: how the COVID-19 pandemic has changed outpatient diagnosis in the andrological setting. *J Endocrinol Invest*. 2022 Feb;45(2):463-464. doi: 10.1007/s40618-021-01673-7. Epub 2021 Sep 10. PMID: 34506035; PMCID: PMC8429890.
59. Lania A, Ferrà F, Rubino M, Modica R, Colao A, **Faggiano A**. Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches. *Front Endocrinol (Lausanne)*. 2021 Jul 26;12:651438. doi: 10.3389/fendo.2021.651438. PMID: 34381421; PMCID: PMC8350565.
60. Giannetta E, La Salvia A, Rizza L, Muscogiuri G, Campione S, Pozza C, Colao AAL, **Faggiano A**. Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms? *Front Endocrinol (Lausanne)*. 2021 Jul 22;12:672499. doi: 10.3389/fendo.2021.672499. PMID: 34367064; PMCID: PMC8339959.
61. Barrea L, Muscogiuri G, Pugliese G, Modica R, Laudisio D, Aprano S, **Faggiano A**, Colao A, Savastano S. Chronotype: what role in the context of gastroenteropancreatic neuroendocrine

tumors? *J Transl Med.* 2021 Jul 30;19(1):324. doi: 10.1186/s12967-021-03010-1. PMID: 34330303; PMCID: PMC8325322.

62. **Faggiano A**, Colao A. Editorial-Special Issue: Foreword to the Special Issue on NIKE: Neuroendocrine Tumors, Innovation in Knowledge and Education. *Front Endocrinol (Lausanne).* 2021 Jul 1;12:722145. doi: 10.3389/fendo.2021.722145. PMID: 34276572; PMCID: PMC8281451.
63. Sesti F, Feola T, Puliani G, Centello R, Di Vito V, Bagni O, Lenzi A, Isidori AM, Cantisani V, **Faggiano A**, Giannetta E. Sunitinib Treatment for Advanced Paraganglioma: Case Report of a Novel SDHD Gene Mutation Variant and Systematic Review of the Literature. *Front Oncol.* 2021 Jun 17;11:677983. doi: 10.3389/fonc.2021.677983. PMID: 34221997; PMCID: PMC8247584.
64. Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Colao A, **Faggiano A**; NIKE Group. Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. *Front Endocrinol (Lausanne).* 2021 Jun 18;12:700806. doi: 10.3389/fendo.2021.700806. PMID: 34220723; PMCID: PMC8253222.
65. Zamponi V, Lardo P, Maggio R, Simonini C, Mazzilli R, **Faggiano A**, Pugliese G, Stigliano A. Female Sexual Dysfunction in Primary Adrenal Insufficiency. *J Clin Med.* 2021 Jun 24;10(13):2767. doi: 10.3390/jcm10132767. PMID: 34202462; PMCID: PMC8268403.
66. Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Guarnotta V, Ragni A, Zanata I, Colao A, **Faggiano A**. Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers. *Front Endocrinol (Lausanne).* 2021 May 19;12:665698. doi: 10.3389/fendo.2021.665698. PMID: 34093441; PMCID: PMC8170398.
67. Gallo M, Adinolfi V, Morviducci L, Acquati S, Tuveri E, Ferrari P, Zatelli MC, **Faggiano A**, Argentiero A, Natalicchio A, D'Oronzo S, Danesi R, Gori S, Russo A, Montagnani M, Beretta GD, Di Bartolo P, Silvestris N, Giorgino F. Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. *ESMO Open.* 2021 Jun;6(3):100155. doi: 10.1016/j.esmoop.2021.100155. Epub 2021 May 19. PMID: 34020401; PMCID: PMC8144346.
68. Pacini P, Polti G, **Faggiano A**, Giannetta E, Tarsitano MG, Cantisani V. Multiparametric ultrasound evaluation of a case of bilateral carotid body tumor. *J Ultrasound.* 2021 May 17. doi: 10.1007/s40477-021-00581-z. Epub ahead of print. PMID: 33999368.
69. Silvestris N, Argentiero A, Natalicchio A, D'Oronzo S, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, **Faggiano A**, Ferrari P, Gallo M, Gori S, Morviducci L, Russo A, Tuveri E, Zatelli MC, Montagnani M, Giorgino F. Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. *ESMO Open.* 2021 May 10;6(3):100153. doi: 10.1016/j.esmoop.2021.100153. Epub ahead of print. PMID: 33984679.

70. Albertelli M, Grillo F, Lo Calzo F, Puliani G, Rainone C, Colao AAL, **Faggiano A**; NIKE group. Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask. *Front Endocrinol (Lausanne)*. 2021 Apr 23;12:680305. doi: 10.3389/fendo.2021.680305. PMID: 33967966; PMCID: PMC8104083.
71. Muscogiuri G, Barrea L, Campolo F, Sbardella E, Sciammarella C, Tarsitano MG, Bottiglieri F, Colao A, **Faggiano A**. Ketogenic diet: a tool for the management of neuroendocrine neoplasms? *Crit Rev Food Sci Nutr*. 2020 Oct 14;1-11. doi: 10.1080/10408398.2020.1832955. Epub ahead of print. PMID: 33938778.
72. Di Molfetta S, Dotto A, Fanciulli G, Florio T, Feola T, Colao A, **Faggiano A**. Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer? *Front Endocrinol (Lausanne)*. 2021 Apr 14;12:667784. doi: 10.3389/fendo.2021.667784. PMID: 33935977; PMCID: PMC8081349.
73. Vitale G, Cozzolino A, Malandrino P, Minotta R, Puliani G, Saronni D, **Faggiano A**, Colao A. Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications. *Front Endocrinol (Lausanne)*. 2021 Apr 14;12:665631. doi: 10.3389/fendo.2021.665631. PMID: 33935975; PMCID: PMC8080021.
74. Barrea L, Muscogiuri G, Modica R, Altieri B, Pugliese G, Minotta R, **Faggiano A**, Colao A, Savastano S. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. *Front Endocrinol (Lausanne)*. 2021 Mar 18;12:649496. doi: 10.3389/fendo.2021.649496. PMID: 33815296; PMCID: PMC8018238.
75. Feola T, Centello R, Sesti F, Puliani G, Verrico M, Di Vito V, Di Gioia C, Bagni O, Lenzi A, Isidori AM, Giannetta E, **Faggiano A**. Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review. *Cancers (Basel)*. 2021 Mar 12;13(6):1247. doi: 10.3390/cancers13061247. PMID: 33809007; PMCID: PMC7999788.
76. Vitale G, **Faggiano A**. Foreword to the special issue on advances in neuroendocrine neoplasms. *Rev Endocr Metab Disord*. 2021 Mar 12. doi: 10.1007/s11154-021-09639-z. Epub ahead of print. PMID: 33712996.
77. Massironi S, Campana D, Pusceddu S, Albertelli M, **Faggiano A**, Panzuto F, Smiroldo V, Andreasi V, Rossi RE, Maggio I, Torchio M, Dotto A, Modica R, Rinzivillo M, Carnaghi C, Partelli S, Fanetti I, Lamberti G, Corti F, Ferone D, Colao A, Annibale B, Invernizzi P, Falconi M; ItaNet (Italian Association for Neuroendocrine Tumours) Study Group. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. *Dig Liver Dis*. 2021 Mar;53(3):367-374. doi: 10.1016/j.dld.2020.09.031. Epub 2020 Oct 22. PMID: 33645508.
78. Gallo M, Campione S, Di Vito V, Fortunati N, Lo Calzo F, Messina E, Ruggeri RM, **Faggiano A**, Colao AAL. Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues. *Front Endocrinol (Lausanne)*. 2021 Jan 26;11:610230. doi: 10.3389/fendo.2020.610230. PMID: 33584543; PMCID: PMC7874233.
79. Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Rubino M, de Cicco F, Colao A, **Faggiano A**, Nike Group. Emerging Therapies in Pheochromocytoma and Paraganglioma:

Immune Checkpoint Inhibitors in the Starting Blocks. *J Clin Med*. 2020 Dec 29;10(1):88. doi: 10.3390/jcm10010088. PMID: 33383673; PMCID: PMC7795591.

80. Grossrubatscher E, Fanciulli G, Pes L, Sesti F, Dolci C, de Cicco F, Colao A, **Faggiano A**, Nike Group. Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy. *J Clin Med*. 2020 Oct 29;9(11):3507. doi: 10.3390/jcm9113507. PMID: 33138305; PMCID: PMC7693147.
81. Giannetta E, Guarnotta V, Altieri B, Sciammarella C, Guadagno E, Malandrino P, Puliani G, Feola T, Isidori AM, Colao AAL, **Faggiano A**. ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. *Eur J Endocrinol*. 2020 Dec;183(6):R197-R215. doi: 10.1530/EJE-20-0506. PMID: 33112280.
82. Scandurra C, Modica R, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, Di Vito V, Bottiglieri F, de Cicco F, Giannetta E, Isidori AM, Lenzi A, Muzii B, **Faggiano A**, Colao A. Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience. *J Clin Endocrinol Metab*. 2021 Jan 1;106(1):e316-e327. doi: 10.1210/clinem/dgaa760. PMID: 33084861.
83. Albertelli M, Dotto A, Di Dato C, Malandrino P, Modica R, Versari A, Colao A, Ferone D, **Faggiano A**; NIKE. PRRT: identikit of the perfect patient. *Rev Endocr Metab Disord*. 2020 Sep 25. doi: 10.1007/s11154-020-09581-6. Epub ahead of print. PMID: 32978685.
84. Vitale G, Dicitore A, Barrea L, Sbardella E, Razzore P, Campione S, **Faggiano A**, Colao A; NIKE, Albertelli M, Altieri B, Bottiglieri F, De Cicco F, Di Molfetta S, Fanciulli G, Feola T, Ferone D, Ferrà F, Gallo M, Giannetta E, Grillo F, Grossrubatscher E, Guadagno E, Guarnotta V, Isidori AM, Lania A, Lenzi A, Calzo FL, Malandrino P, Messina E, Modica R, Muscogiuri G, Pes L, Pizza G, Pofi R, Puliani G, Rainone C, Rizza L, Rubino M, Ruggieri RM, Sesti F, Venneri MA, Zatelli MC. From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? *Rev Endocr Metab Disord*. 2020 Sep 15. doi: 10.1007/s11154-020-09589-y. Epub ahead of print. PMID: 32935263.
85. Panzuto F, Maccauro M, Campana D, **Faggiano A**, Massironi S, Pusceddu S, Spada F, Ferone D, Modica R, Grana CM, Ferolla P, Rinzivillo M, Badalamenti G, Zatelli MC, Gelsomino F, De Carlo E, Bartolomei M, Brizzi MP, Cingarlini S, Versari A, Fanciulli G, Arvat E, Merola E, Cives M, Tafuto S, Baldari S, Falconi M. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). *J Endocrinol Invest*. 2020 Aug 16:1–6. doi: 10.1007/s40618-020-01393-4. Epub ahead of print. PMID: 32803662; PMCID: PMC7429140.
86. Sciammarella C, Luce A, Riccardi F, Mocerino C, Modica R, Berretta M, Misso G, Cossu AM, Colao A, Vitale G, Necas A, Fedacko J, Galdiero M, Correale P, **Faggiano A**, Caraglia M, Capasso A, Grimaldi A. Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. *Front Oncol*. 2020 Jul 7;10:1047. doi: 10.3389/fonc.2020.01047. PMID: 32766136; PMCID: PMC7379869.
87. Feola T, Puliani G, Sesti F, Modica R, Biffoni M, Di Gioia C, Carletti R, Anastasi E, Di Vito V, Centello R, Lenzi A, Isidori AM, **Faggiano A**, Giannetta E. Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature. *Front Endocrinol (Lausanne)*. 2020 Jul 16;11:397. doi: 10.3389/fendo.2020.00397. PMID: 32765421;

PMCID: PMC7378381.

88. Verde F, Galatola R, Romeo V, Perillo T, Liuzzi R, Camera L, Klain M, Modica R, **Faggiano A**, Napolitano V, Colao A, Brunetti A, Maurea S. Pancreatic Neuroendocrine Tumors in patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences. *Neuroendocrinology*. 2020 Jun 24. doi: 10.1159/000509647. Epub ahead of print. PMID: 32580192.
89. Pozza C, Sesti F, Di Dato C, Sbardella E, Pofi R, Schiavi F, Bonifacio V, Isidori AM, **Faggiano A**, Lenzi A, Giannetta E. A Novel MAX Gene Mutation Variant in a Patient With Multiple and "Composite" Neuroendocrine-Neuroblastic Tumors. *Front Endocrinol (Lausanne)*. 2020 May 19;11:234. doi: 10.3389/fendo.2020.00234. PMID: 32508744; PMCID: PMC7249266.
90. Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarnotta V, Malandrino P, Messina E, Venneri MA, Giannetta E, Ferone D, Colao A, **Faggiano A**; NIKE group. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. *Endocrine*. 2020 Aug;69(2):441-450. doi: 10.1007/s12020-020-02331-3. Epub 2020 May 28. PMID: 32468269.
91. Altieri B, Di Dato C, Modica R, Bottiglieri F, Di Sarno A, Pittaway JFH, Martini C, **Faggiano A**, Colao A. Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. *Nutrients*. 2020 Apr 8;12(4):1021. doi: 10.3390/nu12041021. PMID: 32276412; PMCID: PMC7230756.
92. Cimmino I, **Faggiano A**, Perruolo G, Modica R, Bottiglieri F, Covelli B, Colao A, Beguinot F, Formisano P, Oriente F. Diagnosis of Flier's syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature. *Endocrine*. 2020 Jul;69(1):73-78. doi: 10.1007/s12020-020-02287-4. Epub 2020 Apr 9. PMID: 32274699.
93. Muscogiuri G, Barrea L, Feola T, Gallo M, Messina E, Venneri MA, **Faggiano A**, Colao A; NIKE (Neuroendocrine Tumors, Innovation in Knowledge and Education) Group. Pancreatic Neuroendocrine Neoplasms: Does Sex Matter? *Trends Endocrinol Metab*. 2020 Sep;31(9):631-641. doi: 10.1016/j.tem.2020.02.010. Epub 2020 Mar 26. PMID: 32223919.
94. Brighi N, Panzuto F, Modica R, Gelsomino F, Albertelli M, Pusceddu S, Massironi S, Lamberti G, Rinzi M, **Faggiano A**, Spallanzani A, Ferone D, Prinzi N, Rossi RE, Annibale B, Colao AM, Campana D. Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. *Oncologist*. 2020 Mar;25(3):259-265. doi: 10.1634/theoncologist.2019-0403. Epub 2019 Nov 6. PMID: 32162819; PMCID: PMC7066710.
95. Fanciulli G, Ruggeri RM, Grossrubatscher E, Calzo FL, Wood TD, **Faggiano A**, Isidori A, Colao A; NIKE. Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. *Rev Endocr Metab Disord*. 2020 Dec;21(4):599-612. doi: 10.1007/s11154-020-09547-8. PMID: 32152781.
96. Filippella M, Altieri B, Falchetti A, Cosso R, Cena H, Musso C, Geronutti E, Rassat L, Cipriani G, Colao A, Di Somma C, **Faggiano A**. Bone metabolism, bone mass and structural integrity profile in professional male football players. *J Sports Med Phys Fitness*. 2020 Jun;60(6):912-918. doi: 10.23736/S0022-4707.20.09913-2. Epub 2020 Feb 27. PMID: 32118386.



97. Cozzolino A, Pozza C, Pofi R, Sbardella E, **Faggiano A**, Isidori AM, Giannetta E, Pernazza A, Rullo E, Ascoli V, Lenzi A, Gianfrilli D. Predictors of malignancy in high-risk indeterminate (TIR3B) cytopathology thyroid nodules. *J Endocrinol Invest*. 2020 Aug;43(8):1115-1123. doi: 10.1007/s40618-020-01200-0. Epub 2020 Feb 25. PMID: 32100197.
98. Puliani G, Sesti F, Feola T, Di Leo N, Polti G, Verrico M, Modica R, Colao A, Lenzi A, Isidori AM, Cantisani V, Giannetta E, **Faggiano A**. Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family. *J Clin Med*. 2020 Feb 21;9(2):588. doi: 10.3390/jcm9020588. PMID: 32098148; PMCID: PMC7074269.
99. Guadagno E, Cervasio M, De Rosa F, Modica R, **Faggiano A**, Del Basso De Caro M. An incidental rectal neuroendocrine microcarcinoma ('micro-NEC') coexistent with a high grade adenoma. *Pathol Int*. 2020 May;70(5):300-302. doi: 10.1111/pin.12916. Epub 2020 Feb 20. PMID: 32080935.
100. Veltroni A, Cosaro E, Spada F, Fazio N, **Faggiano A**, Colao A, Pusceddu S, Zatelli MC, Campana D, Piovesan A, Pia A, Grossrubatscher EM, Filice A, Bianchi A, Razzore P, Toiari M, Cingarlini S, Landoni L, Micciolo R, Davì MV. Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. *Eur J Endocrinol*. 2020 Apr;182(4):439-446. doi: 10.1530/EJE-19-0989. PMID: 32061159.
101. Vitale G, Carra S, Ferraù F, Guadagno E, **Faggiano A**, Colao A; NIKE. Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications. *Crit Rev Oncol Hematol*. 2020 Feb;146:102840. doi: 10.1016/j.critrevonc.2019.102840. Epub 2019 Dec 23. PMID: 31918344.
102. Altieri B, Cavalier E, Bhattoa HP, Pérez-López FR, López-Baena MT, Pérez-Roncero GR, Chedraui P, Annweiler C, Della Casa S, Zelzer S, Herrmann M, **Faggiano A**, Colao A, Holick MF. Vitamin D testing: advantages and limits of the current assays. *Eur J Clin Nutr*. 2020 Feb;74(2):231-247. doi: 10.1038/s41430-019-0553-3. Epub 2020 Jan 6. PMID: 31907366.
103. Bellevicine C, Migliatico I, Sgariglia R, Nacchio M, Vigliar E, Pisapia P, Iaccarino A, Bruzzese D, Fonderico F, Salvatore D, Biondi B, Masone S, Novizio V, Scavuzzo F, Serino D, De Palma M, Chiofalo MG, Botti G, Pezzullo L, Nuzzo V, Spiezia S, De Chiara G, Iorio S, Conzo G, Docimo G, **Faggiano A**, Bongiovanni M, Malapelle U, Colao A, Triassi M, Troncone G; Tiroide Network. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPAR $\alpha$  alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. *Cancer Cytopathol*. 2020 Feb;128(2):107-118. doi: 10.1002/cncy.22217. Epub 2019 Dec 10. PMID: 31821746.
104. Rizza L, Sbardella E, Gianfrilli D, Lauretta R, Tenuta M, Del Bene G, Longo F, **Faggiano A**, Lenzi A, Giannetta E, Pozza C. Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma. *Endocrine*. 2020 Mar;67(3):597-604. doi: 10.1007/s12020-019-02088-4. Epub 2019 Nov 2. PMID: 31679139.
105. Panzuto F, Pusceddu S, **Faggiano A**, Rinzivillo M, Brighi N, Prinzi N, Riccardi F, Iannicelli E, Maggio I, Femia D, Tafuto S, Manuzzi L, Di Sarno A, Annibale B, de Braud F, Campana D; Itanet (Italian Association for Neuroendocrine Tumours). Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal

localizations. *Pancreatology*. 2019 Dec;19(8):1067-1073. doi: 10.1016/j.pan.2019.09.015. Epub 2019 Sep 30. PMID: 31587962.

106. **Faggiano A**, Modica R, Lo Calzo F, Camera L, Napolitano V, Altieri B, de Cicco F, Bottiglieri F, Sesti F, Badalamenti G, Isidori AM, Colao A. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. *J Clin Endocrinol Metab*. 2020 Jan 1;105(1):dgz007. doi: 10.1210/clinem/dgz007. PMID: 31586182.
107. Lamberti G, **Faggiano A**, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, Gelsomino F, De Divitiis C, Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. *J Clin Endocrinol Metab*. 2020 Jan 1;105(1):dgz035. doi: 10.1210/clinem/dgz035. PMID: 31545377.
108. Altieri B, Di Dato C, Martini C, Sciammarella C, Di Sarno A, Colao A, **Faggiano A**; NIKE Group. Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. *Cancers (Basel)*. 2019 Sep 8;11(9):1332. doi: 10.3390/cancers11091332. PMID: 31500357; PMCID: PMC6770134.
109. Panzuto F, Campana D, Massironi S, **Faggiano A**, Rinzivillo M, Lamberti G, Sciola V, Lahner E, Manuzzi L, Colao A, Annibale B. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. *Dig Liver Dis*. 2019 Oct;51(10):1456-1460. doi: 10.1016/j.dld.2019.04.016. Epub 2019 Jun 5. PMID: 31175013.
110. Mantovani G, Isidori AM, Moretti C, Di Dato C, Greco E, Ciolli P, Bonomi M, Petrone L, Fumarola A, Campagna G, Vannucchi G, Di Sante S, Pozza C, **Faggiano A**, Lenzi A, Giannetta E. Selenium supplementation in the management of thyroid autoimmunity during pregnancy: results of the "SERENA study", a randomized, double-blind, placebo-controlled trial. *Endocrine*. 2019 Dec;66(3):542-550. doi: 10.1007/s12020-019-01958-1. Epub 2019 May 25. PMID: 31129812.
111. Giannetta E, Guarnotta V, Rota F, de Cicco F, Grillo F, Colao A, **Faggiano A**; NIKE. A rare rarity: Neuroendocrine tumor of the esophagus. *Crit Rev Oncol Hematol*. 2019 May;137:92-107. doi: 10.1016/j.critrevonc.2019.02.012. Epub 2019 Mar 2. PMID: 31014519.
112. **Faggiano A**, Di Maio S, Mocerino C, Ottaviano M, De Divitiis C, Guarnotta V, Dolce P, Modica R, Puliafito I, Tozzi L, Di Sarno A, Leo S, Riccardi F, Palmieri G, Tafuto S, Bianco A, Badalamenti G, Colao A; ELIOS. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. *Endocrine*. 2019 Nov;66(2):417-424. doi: 10.1007/s12020-019-01894-0. Epub 2019 Mar 14. PMID: 30875056.
113. Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, de la Fouchardière C, Valdes N, Riccardi F, Do Cao C, Bertherat J, Goichot B, Beuschlein F, Drui D, Canu L, Niccoli P, Laboureau S, Tabarin A, Leboulleux S, Calsina B, Libé R, **Faggiano A**, Schlumberger M, Borson-Chazot F, Mannelli M, Gimenez-Roqueplo AP, Caron P, Timmers HJLM, Fassnacht M, Robledo M, Borget I, Baudin E; European Network for the Study of Adrenal Tumors (ENS@T). Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective

Study. *J Clin Endocrinol Metab.* 2019 Jun 1;104(6):2367-2374. doi: 10.1210/jc.2018-01968. PMID: 30715419.

114. Gallo M, Guarnotta V, De Cicco F, Rubino M, **Faggiano A**, Colao A; NIKE Group. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. *J Cancer Res Clin Oncol.* 2019 Feb;145(2):429-443. doi: 10.1007/s00432-019-02839-w. Epub 2019 Jan 7. PMID: 30617553.
115. Marotta V, Russo G, Gambardella C, Grasso M, La Sala D, Chiofalo MG, D'Anna R, Puzziello A, Docimo G, Masone S, Barbato F, Colao A, **Faggiano A**, Grumetto L. Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules. *Chemosphere.* 2019 Mar;218:885-894. doi: 10.1016/j.chemosphere.2018.11.084. Epub 2018 Nov 17. PMID: 30609493.
116. Barrea L, Altieri B, Muscogiuri G, Laudisio D, Annunziata G, Colao A, Faggiano A, Savastano S. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. *Nutrients.* 2018 Dec 1;10(12):1854. doi: 10.3390/nu10121854. PMID: 30513732; PMCID: PMC6316835.
117. Altieri B, Barrea L, Modica R, Muscogiuri G, Savastano S, Colao A, **Faggiano A**. Nutrition and neuroendocrine tumors: An update of the literature. *Rev Endocr Metab Disord.* 2018 Jun;19(2):159-167. doi: 10.1007/s11154-018-9466-z. PMID: 30267297.
118. Massironi S, Campana D, Partelli S, Panzuto F, Rossi RE, **Faggiano A**, Brighi N, Falconi M, Rinzivillo M, Delle Fave G, Colao AM, Conte D. Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. *Ann Surg Oncol.* 2018 Oct;25(11):3200-3206. doi: 10.1245/s10434-018-6673-5. Epub 2018 Jul 27. PMID: 30054824.
119. Marini F, Giusti F, Fossi C, Cioppi F, Cianferotti L, Masi L, Boaretto F, Zovato S, Cetani F, Colao A, Davì MV, **Faggiano A**, Fanciulli G, Ferolla P, Ferone D, Loli P, Mantero F, Marcocci C, Opocher G, Beck-Peccoz P, Persani L, Scillitani A, Guizzardi F, Spada A, Tomassetti P, Tonelli F, Brandi ML. Correction to: Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. *Endocrine.* 2018 Oct;62(1):234-241. doi: 10.1007/s12020-018-1668-3. Erratum for: *Endocrine.* 2018 Oct;62(1):215-233. PMID: 30032405.
120. Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, Spada F, Tafuto S, Massironi S, **Faggiano A**, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D. Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. *Ann Surg.* 2020 Mar;271(3):527-533. doi: 10.1097/SLA.0000000000002939. PMID: 29995678.
121. Altieri B, Colao A, **Faggiano A**. The role of insulin-like growth factor system in the adrenocortical tumors. *Minerva Endocrinol.* 2019 Mar;44(1):43-57. doi: 10.23736/S0391-1977.18.02882-1. Epub 2018 Jul 2. PMID: 29963827.
122. Grillo F, Florio T, Ferraù F, Kara E, Fanciulli G, **Faggiano A**, Colao AAL. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. *Endocr Relat Cancer.* 2018 May 16. pii: ERC-17-0531. doi: 10.1530/ERC-17-0531. [Epub ahead of print] PubMed PMID: 29769293.

123. Gallo M, Ruggeri RM, Muscogiuri G, Pizza G, **Faggiano A**, Colao A; NIKE Group. Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any? *Cancer Treat Rev*. 2018 Jun;67:1-9. doi: 10.1016/j.ctrv.2018.04.013. Epub 2018 May 2. Review. PubMed PMID: 29746922.
124. Zatelli MC, Guadagno E, Messina E, Lo Calzo F, **Faggiano A**, Colao A; NIKE Group. Open issues on G3 neuroendocrine neoplasms: back to the future. *Endocr Relat Cancer*. 2018 Jun;25(6):R375-R384. doi: 10.1530/ERC-17-0507. Epub 2018 Apr 18. Review. PubMed PMID: 29669844.
125. Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, **Faggiano A**, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology*. 2018 Apr 12. pii: S0016-5085(18)30443-8. doi: 10.1053/j.gastro.2018.04.010. [Epub ahead of print] PubMed PMID: 29655834.
126. Vitale G, Dicitore A, Sciammarella C, Di Molfetta S, Rubino M, **Faggiano A**, Colao A. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. *Endocr Relat Cancer*. 2018 Jun;25(6):R351-R364. doi: 10.1530/ERC-18-0010. Epub 2018 Apr 11. Review. PubMed PMID: 29643113.
127. Saponaro F, Cetani F, Repaci A, Pagotto U, Cipriani C, Pepe J, Minisola S, Cipri C, Vescini F, Scillitani A, Salcuni A, Palmieri S, Eller-Vainicher C, Chiodini I, Madeo B, Kara E, Castellano E, Borretta G, Gianotti L, Romanelli F, Camozzi V, **Faggiano A**, Corbetta S, Cianferotti L, Brandi ML, De Feo ML, Palermo A, Vezzoli G, Maino F, Scalese M, Marcocci C. Clinical presentation and management of patients with primary hyperparathyroidism in Italy. *J Endocrinol Invest*. 2018 Apr 3. doi: 10.1007/s40618-018-0879-z. [Epub ahead of print] PubMed PMID: 29616419.
128. **Faggiano A**, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. *Endocrine*. 2018 Mar 23. doi: 10.1007/s12020-018-1583-7. [Epub ahead of print] PubMed PMID: 29572709.
129. Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregini E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, **Faggiano A**, Giuffrida D, Henu K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; NEPScore Working Group. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocr Relat Cancer*. 2018 Jun;25(6):607-618. doi: 10.1530/ERC-17-0489. Epub 2018 Mar 20. PubMed PMID: 29559553; PubMed Central PMCID: PMC5920017.

130. Marcucci G, Cianferotti L, Parri S, Altieri P, Arvat E, Benvenga S, Betterle C, Bondanelli M, Boscaro M, Camozzi V, Centaro GM, Cetani F, Chiodini I, Ciampolillo A, Colao A, Corbetta S, De Feo ML, Uberti ED, **Faggiano A**, Fornari R, Gaspari AL, Giorgino F, Giuliani V, Iacobone M, Innaro N, Lamacchia O, Lenzi A, Mantovani G, Marcocci C, Masi L, Migliaccio S, Palmieri S, Pasquali R, Perigli G, Piccini V, Romagnoli E, Ruggeri RM, Rulli F, Samà MT, Tomaino G, Trimarchi F, Zatelli MC, Brandi ML. HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. *Calcif Tissue Int.* 2018 Mar 6. doi:10.1007/s00223-018-0411-7. [Epub ahead of print] PubMed PMID: 29511787.
131. Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconicini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, **Faggiano A**, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. *Pancreatol.* 2018 Mar;18(2):198-203. doi: 10.1016/j.pan.2018.01.005. Epub 2018 Jan 12. PubMed PMID: 29361429.
132. Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, **Faggiano A**. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. *Endocr Relat Cancer.* 2018 Jan;25(1):R11-R29. doi: 10.1530/ERC-17-0269. Epub 2017 Oct 24. Review. PubMed PMID: 29066503.
133. Gallo M, Muscogiuri G, Pizza G, Ruggeri RM, Barrea L, **Faggiano A**, Colao A; NIKE Group. The management of neuroendocrine tumors: a nutritional viewpoint. *Crit Rev Food Sci Nutr.* 2017 Oct 11:0. doi: 10.1080/10408398.2017.1390729. [Epub ahead of print] PubMed PMID: 29020456.
134. Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, **Faggiano A**; NIKE group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? *Endocrine.* 2017 Oct 10. doi: 10.1007/s12020-017-1420-4. [Epub ahead of print] Review. PubMed PMID: 29019150.
135. Gallo M, Muscogiuri G, Felicetti F, **Faggiano A**, Trimarchi F, Arvat E, Vigneri R, Colao A. Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. *Metabolism.* 2017 Oct 6. pii: S0026-0495(17)30265-2. doi: 10.1016/j.metabol.2017.09.013. [Epub ahead of print] Review. PubMed PMID: 28993227.
136. Marciello F, Mercier O, Ferolla P, Scoazec JY, Filosso PL, Chapelier A, Guggino G, Monaco R, Grimaldi F, Pizzolitto S, Guygay J, de Latour BR, Giuffrida D, Longchamp E, de Montpreville VT, Fadel É, Colao A, Planchard D, Papotti M, **Faggiano A**, Baudin E. Natural History of Localized and Locally Advanced Lung atypical Carcinoid after Complete Resection: A Joined French-ITALIAN Multicentric Retrospective Study. *Neuroendocrinology.* 2017 Aug 17. doi: 10.1159/000480015. [Epub ahead of print] PubMed PMID: 28813709.
137. **Faggiano A**, Lo Calzo F, Pizza G, Modica R, Colao A. The safety of available treatments options for neuroendocrine tumors. *Expert Opin Drug Saf.* 2017 Oct;16(10):1149-1161. doi: 10.1080/14740338.2017.1354984. Epub 2017 Jul 20. Review. PubMed PMID: 28705090.
138. Marotta V, Sciammarella C, Chiofalo MG, Gambardella C, Bellevicine C, Grasso M, Conzo G, Docimo G, Botti G, Losito S, Troncone G, De Palma M, Giacomelli L, Pezzullo L, Colao A,

**Faggiano A.** Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. *Endocr Relat Cancer.* 2017 Sep;24(9):485-493. doi: 10.1530/ERC-17-0085. Epub 2017 Jul 10. PubMed PMID: 28696209.

139. Del Prete M, Di Sarno A, Modica R, Lassandro F, Giorgio A, Bianco A, Muto M, Gasperi M, Del Prete F, Colao A, Montesarchio V, **Faggiano A**; ENETS Centre of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy). Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. *J Endocrinol Invest.* 2017 Dec;40(12):1373-1380. doi: 10.1007/s40618-017-0723-x. Epub 2017 Jun 30. PubMed PMID: 28667452.
140. Cipolletta Campanile A, Malzone MG, Losito NS, Botti G, Chiofalo MG, **Faggiano A**, Siciliano R, Colao A, Pezzullo L, Fulciniti F. Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study. *Endocr Pathol.* 2017 Jun 21. doi: 10.1007/s12022-017-9488-1. [Epub ahead of print] PubMed PMID: 28639242.
141. Gambardella C, Polistena A, Sanguinetti A, Patrone R, Napolitano S, Esposito D, Testa D, Marotta V, **Faggiano A**, Calò PG, Avenia N, Conzo G. Unintentional recurrent laryngeal nerve injuries following thyroidectomy: Is it the surgeon who pays the bill? *Int J Surg.* 2017 May;41 Suppl 1:S55-S59. doi: 10.1016/j.ijssu.2017.01.112. Review. PubMed PMID: 28506414.
142. Gallo M, Malandrino P, Fanciulli G, Rota F, **Faggiano A**, Colao A; NIKE Group. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. *J Cancer Res Clin Oncol.* 2017 Apr 12. doi: 10.1007/s00432-017-2407-5. [Epub ahead of print] Review. PubMed PMID: 28405826.
143. Zatelli MC, Grossrubatscher EM, Guadagno E, Sciammarella C, **Faggiano A**, Colao A. Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms. *Endocr Relat Cancer.* 2017 Jun;24(6):R223-R237. doi: 10.1530/ERC-17-0091. Epub 2017 Apr 7. Review. PubMed PMID: 28389504.
144. Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, Pivonello R, Pezzullo L, Botti G, Colao A, **Faggiano A**. Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. *Endocrine.* 2017 Feb 27. doi: 10.1007/s12020-017-1269-6. [Epub ahead of print] PubMed PMID: 28243971.
145. Davi' MV, Cosaro E, Piacentini S, Reimondo G, Albiger N, Arnaldi G, **Faggiano A**, Mantovani G, Fazio N, Piovesan A, Arvat E, Grimaldi F, Canu L, Mannelli M, Ambrogio AG, Pecori Giraldo F, Martini C, Lania A, Albertelli M, Ferone D, Zatelli MC, Campana D, Colao A, Scaroni C, Terzolo M, De Marinis L, Cingarlini S, Micciolo R, Francia G. Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. *Eur J Endocrinol.* 2017 Apr;176(4):451-459. doi: 10.1530/EJE-16-0809. PubMed PMID: 28183788.
146. Giusti F, Cianferotti L, Boaretto F, Cetani F, Cioppi F, Colao A, Davi' MV, **Faggiano A**, Fanciulli G, Ferolla P, Ferone D, Fossi C, Giudici F, Gronchi G, Loli P, Mantero F, Marcocci C, Marini F, Masi L, Opocher G, Beck-Peccoz P, Persani L, Scillitani A, Sciortino G, Spada A, Tomassetti P, Tonelli F, Brandi ML. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. *Endocrine.* 2017 Jan 28. doi: 10.1007/s12020-017-1234-4. [Epub ahead of print] PubMed PMID: 28132167.

147. Milione M, Maisonneuve P, Pellegrinelli A, Pusceddu S, Centonze G, Dominoni F, Brambilla C, Rubino M, **Faggiano A**, Buzzoni R, Concas L, Giacomelli L, Coppa J, Mazzaferro V, de Braud F. Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. *Endocrine*. 2016 Nov 30. [Epub ahead of print] PubMed PMID: 27905048.
148. Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, Gambardella C, Grasso M, Antonino A, Annunziata A, Macchia PE, Pivonello R, Santini L, Botti G, Losito S, Pezzullo L, Colao A, **Faggiano A**. Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. *J Clin Endocrinol Metab*. 2017 Feb 1;102(2):661-671. doi: 10.1210/jc.2016-2555. PubMed PMID: 27849428.
149. Vitale G, Gaudenzi G, Circelli L, Manzoni MF, Bassi A, Fioritti N, **Faggiano A**, Colao A; NIKE Group. Animal models of medullary thyroid cancer: state of the art and view to the future. *Endocr Relat Cancer*. 2017 Jan;24(1):R1-R12. Epub 2016 Oct 31. Review. PubMed PMID: 27799362.
150. Pivonello C, Rousaki P, Negri M, Sarnataro M, Napolitano M, Marino FZ, Patalano R, De Martino MC, Sciammarella C, **Faggiano A**, Rocco G, Franco R, Kaltsas GA, Colao A, Pivonello R. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. *Endocrine*. 2017 Jun;56(3):603-620. doi: 10.1007/s12020-016-1079-2. Epub 2016 Sep 29. PubMed PMID: 27688013.
151. Davi MV, Pia A, Guarnotta V, Pizza G, Colao A, **Faggiano A**; NIKE Group. The treatment of hyperinsulinemic hypoglycaemia in adults: an update. *J Endocrinol Invest*. 2017 Jan;40(1):9-20. doi: 10.1007/s40618-016-0536-3. Epub 2016 Sep 13. Review. PubMed PMID: 27624297.
152. Campana D, Ravizza D, Ferolla P, **Faggiano A**, Grimaldi F, Albertelli M, Ricci C, Santini D, Brighi N, Fazio N, Colao A, Ferone D, Tomassetti P. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. *Endocrine*. 2017 Jun;56(3):633-638. doi: 10.1007/s12020-016-1099-y. Epub 2016 Sep 3. PubMed PMID: 27592118.
153. Marotta V, Sciammarella C, Colao A, **Faggiano A**. Application of molecular biology of differentiated thyroid cancer for clinical prognostication. *Endocr Relat Cancer*. 2016 Nov;23(11):R499-R515. Epub 2016 Aug 30. Review. PubMed PMID: 27578827.
154. Vitale G, Dicitore A, Messina E, Sciammarella C, **Faggiano A**, Colao A. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy. *Recent Pat Anticancer Drug Discov*. 2016;11(3):275-82. Review. PubMed PMID:27306881.
155. **Faggiano A**, Malandrino P, Modica R, Agrimi D, Aversano M, Bassi V, Giordano EA, Guarnotta V, Logoluso FA, Messina E, Nicastrò V, Nuzzo V, Sciaraffia M, Colao A. Efficacy and Safety of Everolimus in Extrapaneatic Neuroendocrine Tumor: A Comprehensive Review of Literature. *Oncologist*. 2016 Apr 6. pii: theoncologist.2015-0420. [Epub ahead of print] PubMed PMID: 27053503.
156. Circelli L, Sciammarella C, Guadagno E, Tafuto S, Del Basso de Caro M, Botti G, Pezzullo L, Aria M, Ramundo V, Tatangelo F, Simona Losito N, Ieranò C, D'Alterio C, Izzo F, Ciliberto

G, Colao A, **Faggiano A**, Scala S. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. *Oncotarget*. 2016 Feb 26. doi: 10.18632/oncotarget.7738. [Epub ahead of print] PubMed PMID: 26934559.

157. De Luca S, Fonti R, Camera L, Salvatore B, **Faggiano A**, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. *Ann Nucl Med*. 2016 Apr;30(3):234-41. doi: 10.1007/s12149-015-1056-5. Epub 2016 Jan 11. PubMed PMID: 26753628.
158. **Faggiano A**, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. *Oncotarget*. 2016 Feb 2;7(5):5538-47. doi: 10.18632/oncotarget.6686. PubMed PMID: 26701729.
159. Zatelli MC, Fanciulli G, Malandrino P, Ramundo V, **Faggiano A**, Colao A; NIKE Group. Predictive factors of response to mTOR inhibitors in Neuroendocrine tumours. *Endocr Relat Cancer*. 2016 Mar;23(3):R173-83. doi: 10.1530/ERC-15-0413. Epub 2015 Dec 14. Review. PubMed PMID: 26666705.
160. **Faggiano A**, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A. Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score. *Aliment Pharmacol Ther*. 2015 Oct;42(8):1033-4. doi: 10.1111/apt.13381. PubMed PMID: 26374262.
161. Fraenkel M, **Faggiano A**, Valk GD. Epidemiology of Neuroendocrine Tumors. *Front Horm Res*. 2015;44:1-23. doi: 10.1159/000381970. Epub 2015 Aug 14. PubMed PMID: 26303701.
162. Puzziello A, Guerra A, Murino A, Izzo G, Carrano M, Angrisani E, Zeppa P, Marotta V, **Faggiano A**, Vitale M. Benign thyroid nodules with RAS mutation grow faster. *Clin Endocrinol (Oxf)*. 2016 May;84(5):736-40. doi: 10.1111/cen.12875. Epub 2015 Sep 28. PubMed PMID: 26260959.
163. Lastoria S, Marciello F, **Faggiano A**, Aloj L, Caracò C, Aurilio M, D'Ambrosio L, Di Gennaro F, Ramundo V, Camera L, De Luca L, Fonti R, Napolitano V, Colao A. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). *Endocrine*. 2015 Aug 5. [Epub ahead of print] PubMed PMID: 26242621.
164. Giusti F, Cianferotti L, Gronchi G, Cioppi F, Masi L, **Faggiano A**, Colao A, Ferolla P, Brandi ML. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). *Endocrine*. 2015 Jul 30. [Epub ahead of print] PubMed PMID: 26224587.
165. Stigliano A, Chiodini I, Giordano R, **Faggiano A**, Canu L, Della Casa S, Loli P, Luconi M, Mantero F, Terzolo M. Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE). *J Endocrinol Invest*. 2016 Jan;39(1):103-21. doi: 10.1007/s40618-015-0349-9. Epub 2015 Jul 14. PubMed PMID: 26165270.



166. Fabbrocini G, Izzo R, **Faggiano A**, Del Prete M, Donnarumma M, Marasca C, Marciello F, Savastano R, Monfrecola G, Colao A. Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. *Clin Exp Dermatol*. 2016 Jan;41(1):38-42. doi: 10.1111/ced.12673. Epub 2015 Jun 6. PubMed PMID: 26053680.
167. Maione L, Tortora F, Modica R, Ramundo V, Riccio E, Daniele A, Belfiore MP, Colao A, Pisani A, **Faggiano A**. Pituitary function and morphology in Fabry disease. *Endocrine*. 2015 Nov;50(2):483-8. doi: 10.1007/s12020-015-0604-z. Epub 2015 Apr 21. PubMed PMID: 25896551.
168. Circelli L, Ramundo V, Marotta V, Sciammarella C, Marciello F, Del Prete M, Sabatino L, Pasquali D, Izzo F, Scala S, Colao A, **Faggiano A**, Colantuoni V; Multidisciplinary Group for NeuroEndocrine Tumours of Naples. Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1. *J Cell Mol Med*. 2015 Jul;19(7):1735-41. doi: 10.1111/jcmm.12552. Epub 2015 Mar 30. PubMed PMID: 25824098; PubMed Central PMCID: PMC4511370.
169. Marcocci C, Brandi ML, Scillitani A, Corbetta S, **Faggiano A**, Gianotti L, Migliaccio S, Minisola S. Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism. *J Endocrinol Invest*. 2015 May;38(5):577-93. doi: 10.1007/s40618-015-0261-3. Epub 2015 Mar 28. PubMed PMID: 25820553.
170. Campana D, Ravizza D, Ferolla P, **Faggiano A**, Grimaldi F, Albertelli M, Berretti D, Castellani D, Cacciari G, Fazio N, Colao A, Ferone D, Tomassetti P. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. *Endocrine*. 2016 Jan;51(1):131-9. doi: 10.1007/s12020-015-0584-z. Epub 2015 Mar 27. PubMed PMID: 25814125.
171. Marotta V, Colao A, **Faggiano A**. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. *Endocrine*. 2015 Dec;50(3):824-5. doi: 10.1007/s12020-015-0570-5. Epub 2015 Mar 10. PubMed PMID: 25754914.
172. Modica R, Colao A, **Faggiano A**. Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery. *J Endocrinol Invest*. 2015 Mar;38(3):373-4. doi: 10.1007/s40618-014-0221-3. Epub 2014 Dec 6. PubMed PMID: 25480427.
173. Marcucci G, Cianferotti L, Beck-Peccoz P, Capezzone M, Cetani F, Colao A, Davì MV, degli Uberti E, Del Prato S, Elisei R, **Faggiano A**, Ferone D, Foresta C, Fugazzola L, Ghigo E, Giacchetti G, Giorgino F, Lenzi A, Malandrino P, Mannelli M, Marcocci C, Masi L, Pacini F, Opocher G, Radicioni A, Tonacchera M, Vigneri R, Zatelli MC, Brandi ML. Rare diseases in clinical endocrinology: a taxonomic classification system. *J Endocrinol Invest*. 2015 Feb;38(2):193-259. doi: 10.1007/s40618-014-0202-6. Epub 2014 Nov 7. PubMed PMID: 25376364.
174. Camera L, Severino R, **Faggiano A**, Masone S, Mansueto G, Maurea S, Fonti R, Salvatore M. Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic

vipoma. *World J Radiol.* 2014 Oct 28;6(10):840-5. doi: 10.4329/wjr.v6.i10.840. PubMed PMID: 25349667; PubMed Central PMCID: PMC4209429.

175. Marotta V, Di Somma C, Rubino M, Sciammarella C, Modica R, Camera L, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Colao A, **Faggiano A**. Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib. *Endocrine.* 2015 Aug;49(3):854-8. doi: 10.1007/s12020-014-0448-y. Epub 2014 Oct 11. PubMed PMID: 25305056.
176. Marotta V, Sciammarella C, Vitale M, Colao A, **Faggiano A**. The evolving field of kinase inhibitors in thyroid cancer. *Crit Rev Oncol Hematol.* 2015 Jan;93(1):60-73. doi: 10.1016/j.critrevonc.2014.08.007. Epub 2014 Sep 16. Review. PubMed PMID: 25240824.
177. Marotta V, Di Somma C, Rubino M, Sciammarella C, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Modica R, Vitale M, Colao A, **Faggiano A**. Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. *Endocrine.* 2015 May;49(1):274-8. doi: 10.1007/s12020-014-0381-0. Epub 2014 Aug 15. PubMed PMID: 25123977.
178. Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, **Faggiano A**, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Carteni G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. Real-world study of everolimus in advanced progressive neuroendocrine tumors. *Oncologist.* 2014 Sep;19(9):966-74. doi: 10.1634/theoncologist.2014-0037. Epub 2014 Aug 12. Erratum in: *Oncologist.* 2015 May;20(5):570. PubMed PMID: 25117065; PubMed Central PMCID: PMC4153458.
179. Muscogiuri G, Cignarelli A, Giorgino F, Prodam F, Santi D, Tirabassi G, Balercia G, Modica R, **Faggiano A**, Colao A. GLP-1: benefits beyond pancreas. *J Endocrinol Invest.* 2014 Dec;37(12):1143-53. doi: 10.1007/s40618-014-0137-y. Epub 2014 Aug 9. Review. Erratum in: *J Endocrinol Invest.* 2015 Jan;38(1):115. Prodam, F [corrected to Prodam, F]. PubMed PMID: 25107343.
180. Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Davì MV, D'Elia AV, **Faggiano A**, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. *J Endocrinol Invest.* 2014 Sep;37(9):875-909. doi: 10.1007/s40618-014-0119-0. Epub 2014 Jul 20. PubMed PMID: 25038902; PubMed Central PMCID: PMC4159596.
181. Puzziello A, Carrano M, Angrisani E, Marotta V, **Faggiano A**, Zeppa P, Vitale M. Evolution of benign thyroid nodules under levothyroxine non-suppressive therapy. *J Endocrinol Invest.* 2014 Dec;37(12):1181-6. doi: 10.1007/s40618-014-0128-z. Epub 2014 Jul 10. PubMed PMID: 25008459.
182. Del Prete M, Fiore F, Modica R, Marotta V, Marciello F, Ramundo V, Di Sarno A, Carratù A, di Roseto Cde L, Tafuto S, Tatangelo F, Baldelli R, Colao A, **Faggiano A**; Multidisciplinary Group for NeuroEndocrine Tumors of Naples. Hepatic arterial embolization in patients with

neuroendocrine tumors. *J Exp Clin Cancer Res*. 2014 May 19;33:43. doi: 10.1186/1756-9966-33-43. Review. PubMed PMID: 24887262; PubMed Central PMCID: PMC4038067.

183. Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, De Luca L, Circelli L, Colantuoni V, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, **Faggiano A**; Multidisciplinary Group for Neuroendocrine Tumors of Naples. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. *Clin Endocrinol (Oxf)*. 2014 Jun;80(6):850-5. doi: 10.1111/cen.12411. Epub 2014 Feb 19. PubMed PMID: 24443791.
184. Marciello F, Di Somma C, Del Prete M, Marotta V, Ramundo V, Carratù A, de Luca di Roseto C, Camera L, Colao A, **Faggiano A**. Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas. *Endocrine*. 2014 Aug;46(3):678-81. doi: 10.1007/s12020-013-0145-2. Epub 2014 Jan 3. PubMed PMID: 24385268.
185. Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, **Faggiano A**. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. *Endocrine*. 2014 Sep;47(1):177-82. doi: 10.1007/s12020-013-0130-9. Epub 2014 Jan 3. PubMed PMID: 24385266.
186. Iannaci G, Luise R, Sapere P, Coluccino V, Ronchi A, **Faggiano A**, Marotta V, Colao A, Spiezia S. Fibrous Variant of Hashimoto's Thyroiditis as a Diagnostic Pitfall in Thyroid Pathology. *Case Rep Endocrinol*. 2013;2013:308908. doi: 10.1155/2013/308908. Epub 2013 Dec 5. PubMed PMID: 24381770; PubMed Central PMCID: PMC3870128.
187. Fraenkel M, Kim M, **Faggiano A**, de Herder WW, Valk GD; Knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. *Endocr Relat Cancer*. 2014 May 6;21(3):R153-63. doi: 10.1530/ERC-13-0125. Print 2014 Jun. Review. PubMed PMID: 24322304.
188. Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, **Faggiano A**. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. *Minerva Endocrinol*. 2013 Dec;38(4):389-94. PubMed PMID: 24285106.
189. Guerra A, Di Stasi V, Zeppa P, **Faggiano A**, Marotta V, Vitale M. BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay. *Endocrine*. 2014 Mar;45(2):249-55. doi: 10.1007/s12020-013-9994-y. Epub 2013 Jun 18. PubMed PMID: 23775008.
190. Marotta V, Franzese MD, Del Prete M, Chiofalo MG, Ramundo V, Esposito R, Marciello F, Pezzullo L, Carratù A, Vitale M, Colao A, **Faggiano A**. Targeted therapy with kinase inhibitors in aggressive endocrine tumors. *Expert Opin Pharmacother*. 2013 Jun;14(9):1187-203. doi: 10.1517/14656566.2013.796931. Review. PubMed PMID: 23675883.
191. Fraenkel M, Kim MK, **Faggiano A**, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. *Best Pract Res Clin Gastroenterol*. 2012 Dec;26(6):691-703. doi: 10.1016/j.bpg.2013.01.006. Review. PubMed PMID: 23582913.

192. Russo E, Guerra A, Marotta V, **Faggiano A**, Colao A, Del Vecchio S, Tonacchera M, Vitale M. Radioiodide induces apoptosis in human thyroid tissue in culture. *Endocrine*. 2013 Dec;44(3):729-34. doi: 10.1007/s12020-013-9940-z. Epub 2013 Mar 31. PubMed PMID: 23543460.
193. Marotta V, Guerra A, Zatelli MC, Uberti ED, Di Stasi V, **Faggiano A**, Colao A, Vitale M. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present. *Clin Endocrinol (Oxf)*. 2013 Nov;79(5):733-8. doi: 10.1111/cen.12194. Epub 2013 Apr 1. PubMed PMID: 23469895.
194. Milone F, Pivonello C, Cariati F, Sarnataro M, Ramundo V, Marotta V, Jann H, Pape UF, Wiedenmann B, Colao A, Pavel M, **Faggiano A**. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases. *Biomarkers*. 2013 Mar;18(2):121-5. doi: 10.3109/1354750X.2012.745166. Epub 2013 Jan 22. PubMed PMID: 23336103.
195. Cuccurullo V, **Faggiano A**, Scialpi M, Cascini GL, Piunno A, Catalano O, Colao A, Mansi L. Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors? *Minerva Endocrinol*. 2012 Dec;37(4):367-77. Review. PubMed PMID: 23235192.
196. Di Somma C, Rubino M, **Faggiano A**, Vuolo L, Contaldi P, Tafuri N, Andretti M, Savastano S, Colao A. Spinal deformity index in patients with type 2 diabetes. *Endocrine*. 2013 Jun;43(3):651-8. doi: 10.1007/s12020-012-9848-z. Epub 2012 Dec 11. Erratum in: *Endocrine*. 2013 Jun;43(3):736. Tafuto, N [corrected to Tafuri, N]. PubMed PMID: 23229683.
197. Saponaro F, **Faggiano A**, Grimaldi F, Borretta G, Brandi ML, Minisola S, Frasoldati A, Papini E, Scillitani A, Banti C, Del Prete M, Vescini F, Gianotti L, Cavalli L, Romagnoli E, Colao A, Cetani F, Marcocci C. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. *Clin Endocrinol (Oxf)*. 2013 Jul;79(1):20-6. doi: 10.1111/cen.12108. Epub 2013 Apr 27. PubMed PMID: 23228121.
198. **Faggiano A**, Ramundo V, Assanti AP, Fonderico F, Macchia PE, Misso C, Marciello F, Marotta V, Del Prete M, Papini E, Lombardi G, Colao A, Spiezia S. Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study. *J Clin Endocrinol Metab*. 2012 Dec;97(12):4439-45. doi: 10.1210/jc.2012-2251. Epub 2012 Sep 27. PubMed PMID: 23019349.
199. Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, **Faggiano A**. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. *Clin Endocrinol (Oxf)*. 2013 May;78(5):760-7. doi: 10.1111/cen.12057. PubMed PMID: 23009688.
200. Ramundo V, Ercolino T, **Faggiano A**, Giachè V, Raghianti B, Rapizzi E, Colao A, Mannelli M. Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas. *Front Endocrinol (Lausanne)*. 2012 May 18;3:65. doi: 10.3389/fendo.2012.00065. eCollection 2012. PubMed PMID: 22723792; PubMed Central PMCID: PMC3379562.

201. Vuolo L, Di Somma C, **Faggiano A**, Colao A. Vitamin D and cancer. *Front Endocrinol (Lausanne)*. 2012 Apr 23;3:58. doi: 10.3389/fendo.2012.00058. eCollection 2012. PubMed PMID: 22649423; PubMed Central PMCID: PMC3355893.
202. Del Prete M, Mauriello MC, **Faggiano A**, Di Somma C, Monfrecola G, Fabbrocini G, Colao A. Insulin resistance and acne: a new risk factor for men? *Endocrine*. 2012 Dec;42(3):555-60. doi: 10.1007/s12020-012-9647-6. Epub 2012 Mar 25. PubMed PMID: 22447309.
203. Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G, Vitale M, Colao A, **Faggiano A**. Limitations of Chromogranin A in clinical practice. *Biomarkers*. 2012 Mar;17(2):186-91. doi: 10.3109/1354750X.2012.654511. Epub 2012 Feb 6. PubMed PMID: 22303881.
204. Piccini V, Rapizzi E, Bacca A, Di Trapani G, Pulli R, Giachè V, Zampetti B, Lucci-Cordisco E, Canu L, Corsini E, **Faggiano A**, Deiana L, Carrara D, Tantardini V, Mariotti S, Ambrosio MR, Zatelli MC, Parenti G, Colao A, Pratesi C, Bernini G, Ercolino T, Mannelli M. Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. *Endocr Relat Cancer*. 2012 Apr 10;19(2):149-55. doi: 10.1530/ERC-11-0369. Print 2012 Apr. PubMed PMID: 22241717.
205. Lombardi G, Di Somma C, Rubino M, **Faggiano A**, Vuolo L, Guerra E, Contaldi P, Savastano S, Colao A. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. *J Endocrinol Invest*. 2011 Jul;34(7 Suppl):18-22. Review. PubMed PMID: 21985975.
206. **Faggiano A**, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davi MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. *J Endocrinol Invest*. 2012 Oct;35(9):817-23. doi: 10.3275/8102. Epub 2011 Nov 9. PubMed PMID: 22080849.
207. **Faggiano A**, Del Prete M, Marciello F, Marotta V, Ramundo V, Colao A. Thyroid diseases in elderly. *Minerva Endocrinol*. 2011 Sep;36(3):211-31. Review. PubMed PMID: 22019751.
208. Ramundo V, Milone F, Severino R, Savastano S, Di Somma C, Vuolo L, De Luca L, Lombardi G, Colao A, **Faggiano A**. Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients. *Horm Metab Res*. 2011 Oct;43(11):794-800. doi: 10.1055/s-0031-1286324. Epub 2011 Oct 18. PubMed PMID: 22009375.
209. **Faggiano A**, Ramundo V, Dicitore A, Castiglioni S, Borghi MO, Severino R, Ferolla P, Crinò L, Abbruzzese A, Sperlongano P, Caraglia M, Ferone D, Hofland L, Colao A, Vitale G. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. *J Cell Mol Med*. 2012 Jul;16(7):1563-72. doi: 10.1111/j.1582-4934.2011.01438.x. PubMed PMID: 21883896; PubMed Central PMCID: PMC3823224.
210. Ferolla P, **Faggiano A**, Grimaldi F, Ferone D, Scarpelli G, Ramundo V, Severino R, Bellucci MC, Camera LM, Lombardi G, Angeletti G, Colao A. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine

carcinomas in progression on standard doses. *J Endocrinol Invest.* 2012 Mar;35(3):326-31. doi: 10.3275/7869. Epub 2011 Jul 13. PubMed PMID: 21757992.

211. De Rosa A, Rinaldi C, Tucci T, Pappatà S, Rossi F, Morra VB, **Faggiano A**, Colao A, De Michele G. Co-existence of primary hyperparathyroidism and Parkinson's disease in three patients: an incidental finding? *Parkinsonism Relat Disord.* 2011 Dec;17(10):771-3. doi: 10.1016/j.parkreldis.2011.04.021. Epub 2011 Jul 5. PubMed PMID: 21733736.
212. **Faggiano A**, Severino R, Ramundo V, Russo R, Vuolo L, Del Prete M, Marciello F, Lombardi G, Cianciaruso B, Colao A, Pisani A. Thyroid function in Fabry disease before and after enzyme replacement therapy. *Minerva Endocrinol.* 2011 Mar;36(1):1-5. PubMed PMID: 21460782.
213. **Faggiano A**, Di Somma C, Ramundo V, Severino R, Vuolo L, Coppola A, Panico F, Savastano S, Lombardi G, Colao A, Gasperi M. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. *Endocrine.* 2011 Jun;39(3):283-7. doi: 10.1007/s12020-011-9459-0. Epub 2011 Mar 29. PubMed PMID: 21445714.
214. Camera L, Paoletta S, Mollica C, Milone F, Napolitano V, De Luca L, **Faggiano A**, Colao A, Salvatore M. Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: multidetector-row computed tomography vs. endoscopic ultrasound. *Radiol Med.* 2011 Jun;116(4):595-606. doi: 10.1007/s11547-011-0636-2. Epub 2011 Feb 1. English, Italian. PubMed PMID: 21286942.
215. Grimaldi F, Muser D, Beltrami CA, Machin P, Morelli A, Pizzolitto S, Talmassons G, Marciello F, Colao AA, Monaco R, Monaco G, **Faggiano A**. Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score. *Front Endocrinol (Lausanne).* 2011 Aug 19;2:20. doi: 10.3389/fendo.2011.00020. eCollection 2011. PubMed PMID: 22654796; PubMed Central PMCID: PMC3356093.
216. Colao A, Vitale P, **Faggiano A**. Diabetes and cancer. *Front Endocrinol (Lausanne).* 2011 Aug 19;2:22. doi: 10.3389/fendo.2011.00022. eCollection 2011. PubMed PMID: 22649367; PubMed Central PMCID: PMC3355997.
217. Pasquali D, Circelli L, **Faggiano A**, Pancione M, Renzullo A, Elisei R, Romei C, Accardo G, Coppola VR, De Palma M, Ferolla P, Grimaldi F, Colao A, Colantuoni V. CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. *Eur J Endocrinol.* 2011 Mar;164(3):397-404. doi: 10.1530/EJE-10-0929. Epub 2010 Dec 21. PubMed PMID: 21177330.
218. Colao A, Ochoa AS, Auriemma RS, **Faggiano A**, Pivonello R, Lombardi G. Pituitary carcinomas. *Front Horm Res.* 2010;38:94-108. doi: 10.1159/000318499. Epub 2010 Jul 5. Review. PubMed PMID: 20616500.
219. Colao A, **Faggiano A**, Pivonello R. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. *Prog Brain Res.* 2010;182:281-94. doi: 10.1016/S0079-6123(10)82012-6. PubMed PMID: 20541670.

220. **Faggiano A**, Milone F, Ramundo V, Chiofalo MG, Ventre I, Giannattasio R, Severino R, Lombardi G, Colao A, Pezzullo L. A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal. *J Clin Endocrinol Metab.* 2010 Sep;95(9):E32-6. doi: 10.1210/jc.2010-0045. Epub 2010 Jun 9. PubMed PMID: 20534767.
221. Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Verga U, Boscaro M, Castagna MG, Cappelli C, Zatelli MC, **Faggiano A**, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R; ItaMEN network. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. *Eur J Endocrinol.* 2010 Aug;163(2):301-8. doi: 10.1530/EJE-10-0333. Epub 2010 Jun 1. Erratum in: *Eur J Endocrinol.* 2010 Dec;163(6):963. Uberta, Verga [corrected to Verga, Uberta]. PubMed PMID: 20516206.
222. Filippella MG, **Faggiano A**, Falchetti A, Colao A, Rosa C, Poti C, Musso C, Doveri G, Brandi ML. Risk of fractures and bone abnormalities in postmenopausal women with type 2 diabetes mellitus. *Clin Cases Miner Bone Metab.* 2010 May;7(2):126-9. PubMed PMID: 22460017; PubMed Central PMCID: PMC3004459.
223. Filippella M, Davì MV, Doveri G, Lillaz E, Ciccarelli A, Massimetti E, Toiari M, Falconi M, Colao A, **Faggiano A**. Hyperinsulinemic hypoglycemia associated with ectopic Cushing's syndrome due to a pancreatic endocrine tumor in a Type 2 diabetes mellitus patient: clinical implications of a rare association. *J Endocrinol Invest.* 2011 Mar;34(3):175-9. doi: 10.3275/6975. Epub 2010 Apr 12. PubMed PMID: 20386090.
224. Milone F, Ramundo V, Chiofalo MG, Severino R, Paciolla I, Pezzullo L, Lombardi G, Colao A, **Faggiano A**. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. *Clin Endocrinol (Oxf).* 2010 Jul;73(1):85-8. doi: 10.1111/j.1365-2265.2009.03759.x. Epub 2009 Dec 18. PubMed PMID: 20039894.
225. Spiezia S, Garberoglio R, Milone F, Ramundo V, Caiazzo C, Assanti AP, Deandrea M, Limone PP, Macchia PE, Lombardi G, Colao A, **Faggiano A**. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. *Thyroid.* 2009 Mar;19(3):219-25. doi: 10.1089/thy.2008.0202. PubMed PMID: 19265492.
226. **Faggiano A**, Grimaldi F, Pezzullo L, Chiofalo MG, Caracò C, Mozzillo N, Angeletti G, Santeusano F, Lombardi G, Colao A, Avenia N, Ferolla P. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. *Endocr Relat Cancer.* 2009 Mar;16(1):225-31. doi: 10.1677/ERC-08-0152. Epub 2008 Nov 12. PubMed PMID: 19004986.
227. Pivonello R, De Martino MC, Cappabianca P, De Leo M, **Faggiano A**, Lombardi G, Hofland LJ, Lamberts SW, Colao A. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. *J Clin Endocrinol Metab.* 2009 Jan;94(1):223-30. doi: 10.1210/jc.2008-1533. Epub 2008 Oct 28. PubMed PMID: 18957500.

228. Colao A, Di Somma C, Pivonello R, **Faggiano A**, Lombardi G, Savastano S. Medical therapy for clinically non-functioning pituitary adenomas. *Endocr Relat Cancer*. 2008 Dec;15(4):905-15. doi: 10.1677/ERC-08-0181. Epub 2008 Sep 9. Review. PubMed PMID: 18780796.
229. **Faggiano A**, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. *Clin Endocrinol (Oxf)*. 2008 Nov;69(5):756-62. doi: 10.1111/j.1365-2265.2008.03301.x. Epub 2008 May 14. PubMed PMID: 18485119.
230. Ferolla P, **Faggiano A**, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, Del Basso De Caro ML, Milone F, Scarpelli G, Masone S, Santeusano F, Lombardi G, Angeletti G, Colao A. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. *J Endocrinol Invest*. 2008 Mar;31(3):277-86. Review. PubMed PMID: 18401212.
231. **Faggiano A**, Mansueto G, Ferolla P, Milone F, del Basso de Caro ML, Lombardi G, Colao A, De Rosa G. Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. *J Endocrinol Invest*. 2008 Mar;31(3):216-23. PubMed PMID: 18401203.
232. Pivonello R, De Martino MC, De Leo M, Tauchmanovà L, **Faggiano A**, Lombardi G, Colao A. Cushing's syndrome: aftermath of the cure. *Arq Bras Endocrinol Metabol*. 2007 Nov;51(8):1381-91. Review. PubMed PMID: 18209877.
233. Deandrea M, Limone P, Basso E, Mormile A, Ragazzoni F, Gamarra E, Spiezia S, **Faggiano A**, Colao A, Molinari F, Garberoglio R. US-guided percutaneous radiofrequency thermal ablation for the treatment of solid benign hyperfunctioning or compressive thyroid nodules. *Ultrasound Med Biol*. 2008 May;34(5):784-91. doi: 10.1016/j.ultrasmedbio.2007.10.018. Epub 2008 Jan 22. PubMed PMID: 18207307.
234. Volante M, Brizzi MP, **Faggiano A**, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. *Mod Pathol*. 2007 Nov;20(11):1172-82. Epub 2007 Sep 14. PubMed PMID: 17873898.
235. Spiezia S, Garberoglio R, Di Somma C, Deandrea M, Basso E, Limone PP, Milone F, Ramundo V, Macchia PE, Biondi B, Lombardi G, Colao A, **Faggiano A**. Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients. *J Am Geriatr Soc*. 2007 Sep;55(9):1478-9. PubMed PMID: 17767696.
236. **Faggiano A**, Sabourin JC, Ducreux M, Lumbroso J, Duvillard P, Leboulleux S, Dromain C, Colao A, Schlumberger M, Baudin E. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. *Cancer*. 2007 Jul 15;110(2):265-74. PubMed PMID: 17569104.
237. Colao A, Filippella M, Pivonello R, Di Somma C, **Faggiano A**, Lombardi G. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours.



Eur J Endocrinol. 2007 Apr;156 Suppl 1:S57-63. Review. Erratum in: Eur J Endocrinol. 2007 Oct;157(4):543. PubMed PMID: 17413190.

238. **Faggiano A**, Caillou B, Lacroix L, Talbot M, Filetti S, Bidart JM, Schlumberger M. Functional characterization of human thyroid tissue with immunohistochemistry. *Thyroid*. 2007 Mar;17(3):203-11. PubMed PMID: 17381352.
239. Ferolla P, **Faggiano A**, Avenia N, Milone F, Masone S, Giampaglia F, Puma F, Daddi G, Angeletti G, Lombardi G, Santeusanio F, Colao A. Epidemiology of non-gastroenteropancreatic (neuro)endocrine tumours. *Clin Endocrinol (Oxf)*. 2007 Jan;66(1):1-6. Review. PubMed PMID: 17201794.
240. Pivonello R, Ferone D, de Herder WW, **Faggiano A**, Bodei L, de Krijger RR, Lombardi G, Colao A, Lamberts SW, Hofland LJ. Dopamine receptor expression and function in corticotroph ectopic tumors. *J Clin Endocrinol Metab*. 2007 Jan;92(1):65-9. Epub 2006 Oct 10. PubMed PMID: 17032724.
241. Filippella M, Galland F, Kujas M, Young J, **Faggiano A**, Lombardi G, Colao A, Meduri G, Chanson P. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. *Clin Endocrinol (Oxf)*. 2006 Oct;65(4):536-43. PubMed PMID: 16984249.
242. **Faggiano A**, Pisani A, Milone F, Gaccione M, Filippella M, Santoro A, Vallone G, Tortora F, Sabbatini M, Spinelli L, Lombardi G, Cianciaruso B, Colao A. Endocrine dysfunction in patients with Fabry disease. *J Clin Endocrinol Metab*. 2006 Nov;91(11):4319-25. Epub 2006 Aug 22. PubMed PMID: 16926253.
243. Nuzzo V, Tauchmanová L, Falchetti A, **Faggiano A**, Marini F, Piantadosi S, Brandi ML, Leopaldi L, Colao A. MEN1 family with a novel frameshift mutation. *J Endocrinol Invest*. 2006 May;29(5):450-6. PubMed PMID: 16794369.
244. **Faggiano A**, Leboulleux S, Young J, Schlumberger M, Baudin E. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. *Clin Endocrinol (Oxf)*. 2006 Jan;64(1):110-3. PubMed PMID: 16402938.
245. **Faggiano A**, Melis D, Alfieri R, De Martino M, Filippella M, Milone F, Lombardi G, Colao A, Pivonello R. Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease. *J Clin Endocrinol Metab*. 2005 Dec;90(12):6616-22. Epub 2005 Sep 20. PubMed PMID: 16174722.
246. Pivonello R, **Faggiano A**, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. *Endocrinol Metab Clin North Am*. 2005 Jun;34(2):327-39, viii. Review. PubMed PMID: 15850845.
247. Pellecchia MT, Pivonello R, Salvatore E, **Faggiano A**, Barone P, De Michele G, Lombardi G, Colao A, Filla A. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. *Clin Endocrinol (Oxf)*. 2005 Apr;62(4):428-33. PubMed PMID: 15807873.

248. Pivonello R, Ferone D, Filippella M, **Faggiano A**, De Martino MC, Auriemma RS, Rota F, Lombardi G, Colao A. Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. *J Endocrinol Invest*. 2003;26(8 Suppl):82-8. Review. PubMed PMID: 15233220.
249. **Faggiano A**, Coulot J, Bellon N, Talbot M, Caillou B, Ricard M, Bidart JM, Schlumberger M. Age-dependent variation of follicular size and expression of iodine transporters in human thyroid tissue. *J Nucl Med*. 2004 Feb;45(2):232-7. PubMed PMID: 14960641.
250. **Faggiano A**, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. *J Clin Endocrinol Metab*. 2003 Jun;88(6):2527-33. PubMed PMID: 12788849.
251. **Faggiano A**, Pivonello R, Melis D, Filippella M, Di Somma C, Petretta M, Lombardi G, Colao A. Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. *J Clin Endocrinol Metab*. 2003 May;88(5):2076-80. PubMed PMID: 12727957.
252. Pivonello R, De Bellis A, **Faggiano A**, Di Salle F, Petretta M, Di Somma C, Perrino S, Altucci P, Bizzarro A, Bellastella A, Lombardi G, Colao A. Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. *J Clin Endocrinol Metab*. 2003 Apr;88(4):1629-36. PubMed PMID: 12679449.
253. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, **Faggiano A**, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. *Eur J Endocrinol*. 2003 Mar;148(3):325-31. PubMed PMID: 12611613.
254. Di Somma C, Pivonello R, Loche S, **Faggiano A**, Klain M, Salvatore M, Lombardi G, Colao A. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. *Clin Endocrinol (Oxf)*. 2003 Mar;58(3):302-8. PubMed PMID: 12608935.
255. **Faggiano A**, Talbot M, Baudin E, Bidart JM, Schlumberger M, Caillou B. Differential expression of galectin 3 in solid cell nests and C cells of human thyroid. *J Clin Pathol*. 2003 Feb;56(2):142-3. PubMed PMID: 12560396; PubMed Central PMCID: PMC1769870.
256. Pivonello R, **Faggiano A**, Filippella M, Di Somma C, De Martino MC, Gaccione M, Lombardi G, Colao A. Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration. *J Endocrinol Invest*. 2002 Dec;25(11):932-7. PubMed PMID: 12553551.
257. **Faggiano A**, Talbot M, Lacroix L, Bidart JM, Baudin E, Schlumberger M, Caillou B. Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. *Clin Endocrinol (Oxf)*. 2002 Dec;57(6):813-9. PubMed PMID: 12460332.

258. **Faggiano A**, Pivonello R, Ruosi C, Somma E, Imbimbo M, Filippella M, Lombardi G, Colao A. Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. *Pituitary*. 2001 Aug;4(3):187-93. PubMed PMID: 12138992.
259. **Faggiano A**, Pivonello R, Filippella M, Di Somma C, Orio F Jr, Lombard G, Colao A. Spine abnormalities and damage in patients cured from Cushing's disease. *Pituitary*. 2001 Aug;4(3):153-61. PubMed PMID: 12138988.
260. Filippella M, Cappabianca P, Cavallo LM, **Faggiano A**, Lombardi G, de DE, Colao A. Very delayed hyponatremia after surgery and radiotherapy for a pituitary macroadenoma. *J Endocrinol Invest*. 2002 Feb;25(2):163-8. PubMed PMID: 11929088.
261. **Faggiano A**, Pivonello R, Melis D, Alfieri R, Filippella M, Spagnuolo G, Salvatore F, Lombardi G, Colao A. Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease. *J Endocrinol Invest*. 2002 Feb;25(2):142-51. PubMed PMID: 11929085.
262. Di Somma C, Pivonello R, Loche S, **Faggiano A**, Marzullo P, Di Sarno A, Klain M, Salvatore M, Lombardi G, Colao A. Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. *Clin Endocrinol (Oxf)*. 2002 Feb;56(2):153-8. PubMed PMID: 11874405.
263. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, **Faggiano A**, Lombardi G, Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. *J Clin Endocrinol Metab*. 2001 Nov;86(11):5256-61. PubMed PMID: 11701688.
264. Pellecchia MT, Salvatore E, Pivonello R, **Faggiano A**, Barone P, De Michele G, Colao AM, Filla A. Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. *Neurol Sci*. 2001 Feb;22(1):79-80. PubMed PMID: 11487211.
265. Colao A, **Faggiano A**, Pivonello R, Pecori Giraldi F, Cavagnini F, Lombardi G; Study Group of the Italian Endocrinology Society on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. *Eur J Endocrinol*. 2001 May;144(5):499-507. PubMed PMID: 11331216.
266. Ferone D, Pivonello R, Lastoria S, **Faggiano A**, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. *Clin Endocrinol (Oxf)*. 2001 Apr;54(4):469-77. PubMed PMID: 11318782.
267. Pivonello R, **Faggiano A**, Arrichiello P, Di Sarno A, Di Somma C, Ferone D, Lombardi G, Colao A. Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. *Clin Endocrinol (Oxf)*. 2001 Jan;54(1):97-106. PubMed PMID:11167932.

268. Colao A, Cerbone G, Pivonello R, Klain M, Aimaretti G, **Faggiano A**, Di Somma C, Salvatore M, Lombardi G. Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors. *Pituitary*. 1998 Apr;1(1):59-67. PubMed PMID:11081184.
269. Colao A, Pivonello R, Lastoria S, **Faggiano A**, Ferone D, Lombardi G, Fenzi G. Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. *Eur J Endocrinol*. 2000 Oct;143 Suppl 1:S35-42. Review. PubMed PMID: 11068938.
270. Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, **Faggiano A**, Merola B, Lombardi G. New medical approaches in pituitary adenomas. *Horm Res*. 2000;53 Suppl 3:76-87. Review. PubMed PMID: 10971110.
271. Colao A, Pivonello R, **Faggiano A**, Filippella M, Ferone D, Di Somma C, Cerbone G, Marzullo P, Fenzi G, Lombardi G. Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. *Clin Endocrinol (Oxf)*. 2000 Jul;53(1):13-9. PubMed PMID: 10931076.
272. Colao A, Spiezia S, Di Somma C, Marzullo P, Cerbone G, Pivonello R, **Faggiano A**, Lombardi G. Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. *Eur J Endocrinol*. 2000 Jul;143(1):61-9. PubMed PMID: 10870032.
273. Pivonello R, **Faggiano A**, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. *J Endocrinol Invest*. 1999 Dec;22(11):860-5. PubMed PMID: 10710275.
274. Colao A, Pivonello R, Spiezia S, **Faggiano A**, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G. Persistence of increase cardiovascular risk in patients with Cushing's disease after five years of successful cure. *J Clin Endocrinol Metab*. 1999 Aug;84(8):2664-72. PubMed PMID: 10443657.
275. Pivonello R, **Faggiano A**, Di Somma C, Klain M, Filippella M, Salvatore M, Lombardi G, Colao A. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. *J Clin Endocrinol Metab*. 1999 Jul;84(7):2349-52. PubMed PMID: 10404801.
276. Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G, **Faggiano A**, Corneli G, Ghigo E, Lombardi G. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. *J Clin Endocrinol Metab*. 1999 Jun;84(6):1919-24. PubMed PMID: 10372687.
277. Colao A, Cerbone G, Pivonello R, Aimaretti G, Loche S, Di Somma C, **Faggiano A**, Corneli G, Ghigo E, Lombardi G. The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. *J Clin Endocrinol Metab*. 1999 Apr;84(4):1277-82. PubMed PMID: 10199767.
278. Colao A, Pivonello R, Ferone D, **Faggiano A**, Faccioli G, Di Somma C, Boudouresque F, Oliver C, Lombardi G. Effect of corticotrophin-releasing hormone on arginine vasopressin and

atrial natriuretic factor in patients with Cushing's disease. *Clin Endocrinol (Oxf)*. 1998 Jul;49(1):77-84. PubMed PMID: 9797850.

279. Di Somma C, Colao A, Pivonello R, Klain M, **Faggiano A**, Tripodi FS, Merola B, Salvatore M, Lombardi G. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. *Clin Endocrinol (Oxf)*. 1998 May;48(5):655-62. PubMed PMID: 9666879.
280. Pivonello R, Colao A, Di Somma C, Faccioli G, Klain M, **Faggiano A**, Salvatore M, Lombardi G. Impairment of bone status in patients with central diabetes insipidus. *J Clin Endocrinol Metab*. 1998 Jul;83(7):2275-80. PubMed PMID: 9661594.
281. Colao A, Cerbone G, Cappabianca P, Ferone D, Alfieri A, Di Salle F, **Faggiano A**, Merola B, de Divitiis E, Lombardi G. Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas. *J Endocrinol Invest*. 1998 May;21(5):284-90. PubMed PMID: 9648049.
282. Colao A, Pivonello R, Ferone D, La Tessa G, **Faggiano A**, Faccioli G, Di Somma C, Merola B, Lombardi G. Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. *J Endocrinol Invest*. 1998 Apr;21(4):257-62. PubMed PMID: 9624601.